Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Feb. 21, 2019 | Jun. 30, 2018 | |
Document Document And Entity Information [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2018 | ||
Document Fiscal Year Focus | 2,018 | ||
Document Fiscal Period Focus | FY | ||
Trading Symbol | NVCR | ||
Entity Registrant Name | Novocure Ltd | ||
Entity Central Index Key | 1,645,113 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Common Stock, Shares Outstanding | 94,994,588 | ||
Entity Public Float | $ 1,752,641,027 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 140,622 | $ 78,592 |
Short-term investments | 105,256 | 104,719 |
Restricted cash | 2,134 | 2,126 |
Trade receivables, net | 36,523 | 29,567 |
Receivables and prepaid expenses | 14,279 | 8,105 |
Inventories | 22,555 | 22,025 |
Total current assets | 321,369 | 245,134 |
Long-term assets: | ||
Property and equipment, net | 8,442 | 9,031 |
Field equipment, net | 6,924 | 9,036 |
Severance pay fund | 113 | 111 |
Other long-term assets | 2,945 | 1,986 |
Total long-term assets | 18,424 | 20,164 |
Total assets | 339,793 | 265,298 |
Current liabilities: | ||
Trade payables | 26,708 | 17,206 |
Other payables and accrued expenses | 37,852 | 32,996 |
Total current liabilities | 64,560 | 50,202 |
Long-term liabilities: | ||
Long-term loan, net of discount and issuance costs | 149,268 | 97,342 |
Deferred revenues | 9,929 | 0 |
Employee benefit liabilities | 2,683 | 2,453 |
Other long-term liabilities | 1,094 | 1,737 |
Total long-term liabilities | 162,974 | 101,532 |
Total liabilities | 227,534 | 151,734 |
Commitments and contingencies | 0 | 0 |
Shareholders’ equity: | ||
Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 93,254,185 shares and 89,478,032 shares at December 31, 2018 and December 31, 2017 respectively; | 0 | 0 |
Additional paid-in capital | 757,314 | 697,165 |
Accumulated other comprehensive loss | (1,400) | (1,343) |
Accumulated deficit | (643,655) | (582,258) |
Total shareholders’ equity | 112,259 | 113,564 |
Total liabilities and shareholders’ equity | $ 339,793 | $ 265,298 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Statement Of Financial Position [Abstract] | ||
Common stock, par value | ||
Common stock, shares authorized | Unlimited | Unlimited |
Common stock, shares issued | 93,254,185 | 89,478,032 |
Common stock, shares outstanding | 93,254,185 | 89,478,032 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Income Statement [Abstract] | |||
Net revenues | $ 248,069 | $ 177,026 | $ 82,888 |
Cost of revenues | 80,048 | 55,609 | 39,870 |
Impairment of field equipment | 6,412 | ||
Gross profit | 168,021 | 121,417 | 36,606 |
Operating costs and expenses: | |||
Research, development and clinical trials | 50,574 | 38,103 | 41,467 |
Sales and marketing | 77,663 | 63,528 | 59,449 |
General and administrative | 73,456 | 59,114 | 51,007 |
Total operating costs and expenses | 201,693 | 160,745 | 151,923 |
Operating income (loss) | (33,672) | (39,328) | (115,317) |
Financial income (expenses), net | (12,270) | (9,169) | (6,147) |
Income (loss) before income taxes | (45,942) | (48,497) | (121,464) |
Income taxes | 17,617 | 13,165 | 10,381 |
Net income (loss) | $ (63,559) | $ (61,662) | $ (131,845) |
Basic and diluted net income (loss) per ordinary share | $ (0.69) | $ (0.70) | $ (1.54) |
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share | 91,828,043 | 88,546,719 | 85,558,448 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Statement Of Income And Comprehensive Income [Abstract] | |||
Net income (loss) | $ (63,559) | $ (61,662) | $ (131,845) |
Other comprehensive income (loss), net of tax : | |||
Change in foreign currency translation adjustments | 27 | 8 | 10 |
Pension benefit plan | (84) | 532 | (388) |
Total comprehensive income (loss) | $ (63,616) | $ (61,122) | $ (132,223) |
Statements of Changes in Shareh
Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands | Total | Ordinary Shares | Additional Paid-in Capital | Accumulated Other Comprehensive Income (Loss) | Retained Earnings (Accumulated Deficit) |
Balance at Dec. 31, 2015 | $ 250,820 | $ 640,406 | $ (1,505) | $ (388,081) | |
Balance (in shares) at Dec. 31, 2015 | 83,778,581 | ||||
Share-based compensation to employees | 21,441 | 21,441 | |||
Exercise of options and warrants | 993 | 993 | |||
Exercise of options and warrants (in shares) | 3,195,477 | ||||
Issuance of shares in connection with employee stock purchase plan | 616 | 616 | |||
Issuance of shares in connection with employee stock purchase plan(in shares) | 92,388 | ||||
Tax benefit from share-based award activity | 698 | 698 | |||
Other comprehensive income (loss), net of tax (benefit) expense of $38, $68, and $10 for the years ended December 2016, 2017 and 2018 | (378) | (378) | |||
Net income (loss) | (131,845) | (131,845) | |||
Balance at Dec. 31, 2016 | 142,345 | 664,154 | (1,883) | (519,926) | |
Balance (in shares) at Dec. 31, 2016 | 87,066,446 | ||||
Cumulative effect adjustment resulting from ASU 2016-09 adoption (See Note 2) | 670 | (670) | |||
Share-based compensation to employees | 27,116 | 27,116 | |||
Exercise of options and warrants | 3,685 | 3,685 | |||
Exercise of options and warrants (in shares) | 2,244,153 | ||||
Issuance of shares in connection with employee stock purchase plan | 1,540 | 1,540 | |||
Issuance of shares in connection with employee stock purchase plan(in shares) | 167,433 | ||||
Other comprehensive income (loss), net of tax (benefit) expense of $38, $68, and $10 for the years ended December 2016, 2017 and 2018 | 540 | 540 | |||
Net income (loss) | (61,662) | (61,662) | |||
Balance at Dec. 31, 2017 | 113,564 | 697,165 | (1,343) | (582,258) | |
Balance (in shares) at Dec. 31, 2017 | 89,478,032 | ||||
Share-based compensation to employees | 39,846 | 39,846 | |||
Exercise of options and warrants | 18,468 | 18,468 | |||
Exercise of options and warrants (in shares) | 3,688,781 | ||||
Proceeds from issuance of shares | 1,835 | 1,835 | |||
Proceeds from issuance of shares (in shares) | 87,372 | ||||
Cumulative effect adjustment resulting from ASC 606 adoption (See note 2) | 2,162 | 2,162 | |||
Other comprehensive income (loss), net of tax (benefit) expense of $38, $68, and $10 for the years ended December 2016, 2017 and 2018 | (57) | (57) | |||
Net income (loss) | (63,559) | (63,559) | |||
Balance at Dec. 31, 2018 | $ 112,259 | $ 757,314 | $ (1,400) | $ (643,655) | |
Balance (in shares) at Dec. 31, 2018 | 93,254,185 |
Statements of Changes in Shar_2
Statements of Changes in Shareholders' Equity (Parenthetical) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Other comprehensive income (loss), tax (benefit) expense | $ (10) | $ 68 | $ (38) | |
Series J Preferred Stock | ||||
Share issuance expenses | $ 319 | |||
Over-Allotment | ||||
Share issuance expenses | $ 15,742 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Cash flows from operating activities: | |||
Net income (loss) | $ (63,559) | $ (61,662) | $ (131,845) |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Depreciation and amortization | 9,006 | 7,677 | 5,652 |
Asset write-downs and impairment of field equipment | 407 | 241 | 6,446 |
Share-based compensation | 39,846 | 27,116 | 22,139 |
Excess tax benefits from share-based award activity | (698) | ||
Decrease (increase) in trade receivables, net | (4,151) | (23,228) | (6,339) |
Amortization of discount, net | 1,022 | 252 | 155 |
Decrease (increase) in receivables and prepaid expenses | (6,174) | 1,979 | 243 |
Decrease (increase) in inventories | (529) | 3,524 | (11,955) |
Decrease (increase) in other long-term assets | (949) | (554) | (692) |
Increase (decrease) in trade payables | 9,503 | (1,150) | 1,601 |
Increase (decrease) in other payables and accrued expenses | 4,210 | 14,460 | 6,647 |
Increase (decrease) in employee benefit liabilities, net | 133 | 440 | 97 |
Increase (decrease) in other long-term liabilities | 9,370 | (2,229) | 957 |
Net cash provided by (used in) operating activities | (1,865) | (33,134) | (107,592) |
Cash flows from investing activities: | |||
Purchase of property and equipment | (2,916) | (2,459) | (5,673) |
Purchase of field equipment | (3,795) | (4,907) | (11,990) |
Proceeds from maturity of short-term investments | 255,000 | 120,000 | 270,000 |
Purchase of short-term investments | (253,782) | (104,006) | (239,341) |
Net cash provided by (used in) investing activities | (5,493) | 8,628 | 12,996 |
Cash flows from financing activities: | |||
Proceeds from issuance of shares, net | 1,835 | 1,540 | 616 |
Proceeds from long-term loan, net | 149,150 | 72,887 | |
Repayment of long-term loan | (100,000) | ||
Excess tax benefits from share-based award activity | 698 | ||
Proceeds from issuance of other long-term loans | 19 | ||
Repayment of other long-term loans | (84) | (76) | (70) |
Exercise of options and warrants | 18,468 | 3,685 | 993 |
Net cash provided by financing activities | 69,369 | 5,168 | 75,124 |
Effect of exchange rate changes on cash and cash equivalents | 27 | 8 | 10 |
Increase (decrease) in cash, cash equivalents and restricted cash | 62,038 | (19,330) | (19,462) |
Cash, cash equivalents and restricted cash at the beginning of the year | 80,718 | 100,048 | 119,510 |
Cash, cash equivalents and restricted cash at the end of the year | 142,756 | 80,718 | 100,048 |
Cash paid during the year for: | |||
Income taxes | 20,350 | 10,286 | 9,447 |
Interest | $ 13,334 | $ 10,162 | $ 6,595 |
Organization and Basis of Prese
Organization and Basis of Presentation | 12 Months Ended |
Dec. 31, 2018 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Organization and Basis of Presentation | NovoCure Limited (including its consolidated subsidiaries, the “Company”) was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of Optune for the treatment of a variety of solid tumors. The Company has regulatory approvals and clearances in certain countries for Optune to treat adult patients with glioblastoma (“GBM”). |
Significant Accounting Policies
Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2018 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | The consolidated financial statements are prepared according to United States generally accepted accounting principles (“U.S. GAAP”). a. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, tax liabilities, useful-life of field equipment, revenue recognition and the estimations required in accrual base accounting, and share-based compensation costs. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting period. Actual results could differ from those estimates. b. Financial statements in U.S. dollars: The accompanying financial statements have been prepared in U.S. dollars in thousands, except for share and per-share data. The Company finances its operations in U.S. dollars and a substantial portion of its costs and revenues from its primary markets is incurred in U.S. dollars. As such, the Company’s management believes that the U.S. dollar is the currency of the primary economic environment in which NovoCure Limited and certain subsidiaries operate. The Company’s reporting currency is U.S. dollars. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the U.S. dollar are re-measured into dollars in accordance with Accounting Standards Codification (ASC) No. 830-10, “Foreign Currency Matters.” All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as appropriate. For a subsidiary whose functional currency has been determined to be its local currency, assets and liabilities are translated at year-end exchange rates and statement of operations items are translated at average exchange rates prevailing during the year. Such translation adjustments are recorded as a separate component of accumulated other comprehensive income (loss) in shareholders' equity. c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances, including profits from intercompany sales not yet realized outside the Company, have been eliminated upon consolidation. d. Cash equivalents: Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less at the date acquired. e. Short-term investments and restricted cash: 1. Short-term investments: The Company accounts for investments in debt securities in accordance with ASC 320, “Investments-Debt and Equity Securities.” Management determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. For the years ended December 31, 2018 and 2017, all securities are classified as held-to-maturity since the Company has the intent and ability to hold the securities to maturity and, accordingly, debt securities are stated at amortized cost. The amortized cost of held-to-maturity securities is adjusted for amortization of premiums and accretion of discounts to maturity and any other than temporary impairment losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate. For the three years ended December 31, 2018, no impairment losses have been identified. 2. Restricted cash: The Company has restricted cash used as security for the use of Company credit cards, presented in short-term assets. Additionally, the Company has pledged bank deposits to cover bank guarantees related to facility rental agreements, fleet lease agreements and customs payments presented in other long-term assets (see Note 12). f. Trade receivables: The Company’s trade receivables balance contains billed and unbilled commercial activities. As needed, the Company records an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. The Company periodically reviews its customers’ credit risk and payment history. To date, the Company has not experienced any credit losses related to counter-party risk. g. Inventories: Inventories are stated at the lower of cost or net realizable value. Cost is determined using the weighted average method. The Company regularly evaluates its ability to realize the value of inventory. If the inventories are deemed damaged, if actual demand for the Company’s delivery systems deteriorates, or if market conditions are less favorable than those projected, inventory write-offs may be required. Inventory write-offs of $684, $489 and $774, respectively, were recorded for the years ended December 31, 2018, 2017 and 2016. h. Property and equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life i. Field equipment: Field equipment is stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the field equipment which was determined to be 18 to 36 months. Field equipment is equipment being utilized under service agreements, and accounted for in accordance with ASC 840 on a monthly basis as an operating lease. The Company records a write-off provision for any excess, lost or damaged equipment when warranted based on an assessment of the equipment. Write-offs for equipment are included in cost of revenues. During the years ended December 31, 2018, 2017 and 2016, write-offs for $350, $ 195 and $6,436, respectively, were recorded (see Note 7). j. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360-10, “Property, Plant and Equipment,” whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. During the three years ended December 31, 2018, no impairment losses have been identified other than the impairment of field equipment described below in Note 7. k. Other long-term assets: Longterm lease deposits in respect of office rent and vehicles under operating leases and restricted deposits are presented in other long-term assets. l. Revenue recognition: Optune is comprised of two main components: (1) an electric field generator and (2) transducer arrays and related accessories. We retain title to the electric field generator, and the patient is provided replacement transducer arrays and technical support for the device during the term of treatment. The electric field generator and transducer arrays are always supplied and function together and are not sold on a standalone basis. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU 2014-09), an updated standard on revenue recognition and issued subsequent amendments to the initial guidance in March 2016, April 2016, May 2016 and December 2016 within ASU 2016-08, 2016-10, 2016-12 and 2016-20, respectively (collectively, “ASC 606”). The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods and services to patients in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. In addition, the new standard requires expanded disclosures for all contracts. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605). The amount of revenue recognized in 2018 reflects the consideration to which the Company expects to be entitled to receive in exchange for Optune. The Company uses the portfolio approach to apply the standard to portfolios of contracts with similar characteristics. To recognize revenue under ASC 606, the Company applies the following five steps: 1. Identify the contract with a patient. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to performance obligations in the contract. 5. Recognize revenue when or as the Company satisfies a performance obligation. At adoption of ASC 606, trade receivables increased by $2,807, deferred revenues increased by $645 and the Company recorded a cumulative impact to its accumulated deficit of $2,162. The impact of the Company’s adoption of ASC 606 compared to ASC 605 on the consolidated statements of income for the three months and year ended December 31, 2018 was as follows: net revenue decreased by $4,054 and $8,683, respectively; net loss increased by $4,136 and $8,679, respectively; and our basic and diluted net loss per ordinary share increased by $0.04 and $0.09, respectively. The impact of the Company’s adoption of ASC 606 compared to ASC 605 on the balance sheet as of December 31, 2018 was a decrease in trade receivables of $6,288, an increase to other payables and accrued expenses (deferred revenues net of tax provision) of $1,052 Deferred revenues include amounts invoiced for days of therapy to be provided in future periods. Unbilled revenues include revenues recognized for therapy provided and not invoiced in the reported period, and are presented as part of accounts receivable. Revenues are presented net of indirect taxes of $1,698, $ 1,239 and $ 972 for the years ended December 31, 2018, 2017 and 2016, respectively. Net revenues in 2018 also include amounts recognized pursuant to the Zai Agreement. For additional information, see Note 12. m. Charitable care: The Company provides Optune treatment at no charge to patients who meet certain criteria under its charitable care policy. Because the Company does not pursue collection of amounts determined to qualify as charity, they are not reported as revenue. The Company's costs of care provided under charitable care were $2,762, $1,483 and $ 1,675 for the years ended December 31, 2018, 2017 and 2016, respectively. These amounts were determined by applying charitable care as a percentage of total billings to total cost of goods sold. n. Shipping and handling costs: The Company does not separately bill its customers for shipping and handling costs associated with shipping Optune to its customers. These direct shipping and handling costs of $2,936, $5,322 and $3,389 for the years ended December 31, 2018, 2017 and 2016, respectively are included in Sales and Marketing costs. o. Accounting for share-based payments: The Company accounts for share-based compensation in accordance with ASC 718, “Compensation—Stock Compensation.” ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company recognizes compensation costs for the value of awards granted using the accelerated method over the requisite service period of the award, which is generally the restricted share unit vesting term of three years and option vesting term of four years, respectively. The Company selected the Black-Scholes model as the most appropriate fair value method for all equity awards and the Employee Share Purchase Plan (the “ESPP”). For market condition awards, the Company also applied the Monte-Carlo simulation model. The Black-Scholes model requires a number of assumptions, of which the most significant are the share price, expected volatility and the expected equity award term. The computation of expected volatility is based on actual historical share price volatility of comparable companies. Expected term of options granted is calculated using the average between the vesting period and the contractual term to the expected term of the options in effect at the time of grant. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms. In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted ASU 2016-09 during the quarter ended March 31, 2017, at which time it changed its accounting policy to account for forfeitures as they occur. The change was applied on a modified retrospective basis with a cumulative effect adjustment to accumulated deficit of $670 as of January 1, 2017. In addition, excess tax benefits for share-based payments are now presented as an operating activity in the statements of cash flows rather than financing activity. The changes have been applied prospectively in accordance with the ASU and prior periods have not been adjusted. p. Fair value of financial instruments: The carrying amounts of cash and cash equivalents, short-term investments, restricted cash, receivables and prepaid expenses, trade receivables, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the long-term loans approximate fair value. The Company accounts for certain assets and liabilities at fair value under ASC 820, “Fair Value Measurements and Disclosures.” Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. The three levels of inputs that may be used to measure fair value are as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace, other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets with insufficient volume or infrequent transactions, or other inputs that are observable (model-derived valuations in which significant inputs are observable), or can be derived principally from or corroborated by observable market data; and Level 3 - Unobservable inputs which are supported by little or no market activity. The availability of observable inputs can vary from instrument to instrument and is affected by a wide variety of factors, including, for example, the type of instrument, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the instrument are categorized as Level 3. q. Basic and diluted net loss per share: Basic and diluted net loss per share is computed based on the weighted average number of ordinary shares outstanding during each year. Diluted loss per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus dilutive potential shares considered outstanding during the period, in accordance with ASC 260-10. Basic and diluted net loss per ordinary share was the same for each period presented as the inclusion of all potential ordinary shares (all options and warrants) outstanding was anti-dilutive. r. Income taxes: The Company accounts for income taxes in accordance with ASC 740-10, “Income Taxes.” ASC 740-10 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed. The Company established reserves for uncertain tax positions based on the evaluation of whether or not the Company’s uncertain tax position is “more likely than not” to be sustained upon examination. The Company records interest and penalties pertaining to its uncertain tax positions in the financial statements as income tax expense. s. Concentration of risks: Our cash, cash equivalents, short-term investments and trade receivables are potentially subject to a concentration of risk. Cash, cash equivalents and short-term investments are invested at top tier financial institutions globally. As such these investments may be in excess of insured limitations or not insured in certain jurisdictions. Generally, these investments may be redeemed upon demand and therefore, bear minimal risk. The Company has no off-balance sheet concentrations of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. In 2018, one payer represented $22,959, or 9%, of net revenues. In 2017, the same payer represented $15,479, or 9%, of net revenues. In 2016, the same payer represented $10,393, or 13%, of net revenues. Credit risk with respect to trade receivables is limited. t. Retirement, pension and severance plans: The Company has a 401(k) retirement savings plan for its U.S. employees. Each eligible employee may elect to contribute a portion of the employee’s compensation to the plan. As of December 31, 2018, the Company has not made any matching contributions to this plan. The Company has a defined benefit plan with a pension fund for its Swiss employees, whereby the employee and the Company contribute to the pension fund. The Company accounts for its obligation, in accordance with ASC 715, "Compensation – Retirement Benefits" (see Note 9). The pension expense for the years ended December 31, 2018, 2017 and, 2016 was $882, $ 1,036 and $529, respectively. Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company contributes to employee pension plans to fund its severance liabilities. According to Section 14 of Israel Severance Pay Law, the Company makes deposits on behalf of its employees with respect to the Company’s severance liability and therefore no obligation is provided for in the financial statements. Severance pay liabilities with respect to employees who are not subject to Section 14, are provided for in the financial statements based upon the number of years of service and the latest monthly salary and the related deposits are recorded as an asset based on the cash surrender value. Severance expense for the years ended December 31, 2018, 2017 and 2016 amounted to $526, $506 and $430, respectively. u. Contingent liabilities: The Company accounts for its contingent liabilities in accordance with ASC 450, “Contingencies.” A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December 31, 2018 and 2017, the Company was not a party to any ligation that could have a material adverse effect on the Company’s business, financial position, results of operations or cash flows. v. Other comprehensive income (loss): The Company accounts for comprehensive income (loss) in accordance with ASC 220, "Comprehensive Income". ASC 220 establishes standards for the reporting and display of comprehensive income (loss) and its components. Comprehensive income (loss) generally represents all changes in shareholders' equity during the period except those resulting from investments by, or distributions to, shareholders. The accumulated other comprehensive income (loss), net of taxes, relates to a pension liability and foreign currency translation adjustments. w. Recently adopted accounting pronouncements: ASC 606 – see Note 2(i). ASC 718 – see Note 2(o). In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively as of the earliest date practicable. The Company adopted the standard effective as of January 1, 2018, and t In November 2016, FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. This standard requires the presentation of the statement of cash flows to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents. The standard is effective for fiscal years and the interim periods within those fiscal years beginning after December 15, 2017. The Company adopted the standard retrospectively to all periods presented effective as of January 1, 2018. In March 2017, FASB issued ASU 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Post-retirement Benefit Cost under FASB ASC Topic 715, Retirement Benefits. Accordingly, as of January 1, 2017, the Company reports the current service cost component of net periodic benefit cost in Compensation and benefits on the Company's Consolidated Statements of Income, and reports the other components of net periodic benefit recovery as a separate line item outside of Operating income on the Company's Consolidated Statements of Income. These changes in presentation do not result in any changes to net income or earnings per share. Details of the components of net periodic benefit costs are provided in Note 9 (Pensions and employees benefit obligations). The ASU also prospectively restricts capitalization of net periodic benefit costs to the current service cost component when applicable. This restriction has no impact on the Company's financial statements, since the Company does not capitalize any portion of service cost. x. Recently issued accounting pronouncements: In February 2016, FASB issued ASU 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company adopted the new standard effective January 1, 2019. While the Company is continuing to assess the potential impacts of ASU 2016-02, the Company estimates that the adoption of ASU 2016-02 will result in the recognition of right-of-use assets and lease liabilities for operating leases of approximately $15,733 on its Consolidated Balance Sheets for operation leases and it does not expect an impact on its consolidated statements of operations or debt. In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2020. The amendments in this update are effective for fiscal years beginning after December 31, 2019, including interim periods within those fiscal years. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements, footnote disclosures and employee benefit plans’ accounting. In August 2018, FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The implementation costs incurred in a hosting arrangement that is a service contract should be presented as a prepaid asset in the balance sheet and expensed over the term of the hosting arrangement to the same line item in the statement of income as the costs related to the hosting fees. The guidance in this ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, and early adoption is permitted including adoption in any interim period. The amendments should be applied either retrospectively or prospectively to all implementation costs incurred after adoption. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements and related disclosures. In August 2018, FASB issued ASU 2018-14—Compensation—Retirement Benefits—Defined Benefit Plans—General (Topic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans. ASU 2018-14 improves disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. This standard is effective for fiscal years ending after December 15, 2020, for public business entities. Early adoption is permitted. An entity should apply the amendments in this ASU on a retrospective basis to all periods presented. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements and related disclosures. |
Cash and Cash Equivalents and S
Cash and Cash Equivalents and Short Term Investments | 12 Months Ended |
Dec. 31, 2018 | |
Cash Cash Equivalents And Short Term Investments [Abstract] | |
Cash and Cash equivalents and Short-term investments | Note 3: Cash and Cash equivalents and Short-term investments a. Cash and cash equivalents: Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. December 31, 2018 2017 Cash $ 9,197 $ 5,522 Money market funds 131,425 73,070 Total cash and cash equivalents $ 140,622 $ 78,592 b. Short-term investments The Company invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments. December 31, 2018 2017 Short-term investments $ 105,256 $ 104,719 The estimated fair value of our short-term investments as of December 31, 2018 and 2017 was $105,266 and $104,655, respectively. |
Receivables and Prepaid Expense
Receivables and Prepaid Expenses | 12 Months Ended |
Dec. 31, 2018 | |
Receivables And Prepaid Expenses [Abstract] | |
Receivables and Prepaid Expenses | Note 4: Receivables and prepaid expenses The following table sets forth the Company’s receivables and prepaid expenses: December 31, 2018 2017 Advances to and receivables from suppliers $ 4,565 $ 2,924 Government authorities 6,106 2,006 Prepaid expenses 3,531 2,890 Others 77 285 $ 14,279 $ 8,105 |
Inventories
Inventories | 12 Months Ended |
Dec. 31, 2018 | |
Inventory Disclosure [Abstract] | |
Inventories | Note 5: Inventories The following table sets forth the Company’s inventories: December 31, 2018 2017 Raw materials $ 870 $ 4,276 Work in process 8,667 8,435 Finished goods 13,018 9,314 $ 22,555 $ 22,025 |
Property and Equipment, Net
Property and Equipment, Net | 12 Months Ended |
Dec. 31, 2018 | |
Property Plant And Equipment [Abstract] | |
Property and Equipment, Net | Note 6: Property and equipment, net The following table sets forth the Company’s property and equipment, net: December 31, 2018 2017 Cost: Computers and laboratory equipment $ 12,220 $ 10,833 Office furniture 2,308 2,303 Production equipment 1,228 1,222 Leasehold improvements 4,192 3,614 Total cost $ 19,948 $ 17,972 Accumulated depreciation and amortization (11,506 ) (8,941 ) Depreciated cost $ 8,442 $ 9,031 Depreciation expense was $1,967, $1,968 and $ 1,673 for the years ended December 31, 2018, 2017 and 2016, respectively. The Company capitalized software costs according to FASB ASC 350-40, "Accounting for the costs of Computer Software Developed or Obtained for Internal Use". As of December 31, 2018 and 2017, the Company capitalized an accumulated amount of $6,256 and $5,576, respectively. Amortization for the year ended December 31, 2018 and 2017 was $1,486 and $1,226, respectively. |
Field Equipment, Net
Field Equipment, Net | 12 Months Ended |
Dec. 31, 2018 | |
Field Equipment [Abstract] | |
Field Equipment, Net | Note 7: Field equipment, net The following table sets forth the Company’s field equipment, net: December 31, 2018 2017 Field equipment $ 17,380 $ 15,020 Accumulated depreciation (10,456 ) (5,984 ) Field equipment, net $ 6,924 $ 9,036 Depreciation expense was $5,553, $4,483 and $3,248 for the years ended December 31, 2018, 2017 and 2016, respectively. Write downs of $350, $195, and $6,436 were identified for the years ended December 31, 2018, 2017 and 2016, respectively. The Company made the second generation Optune system available to all patients in the United States in 2016 and manufacturing of the first generation Optune system has been terminated. In 2016, the Company recorded an impairment loss with respect to the write-down of first generation Optune system field equipment in the amount of $ 6,412 |
Other Payables and Accrued Expe
Other Payables and Accrued Expenses | 12 Months Ended |
Dec. 31, 2018 | |
Payables And Accruals [Abstract] | |
Other Payables and Accrued Expenses | Note 8: Other payables and accrued expenses The following table sets forth the Company’s other payables and accrued expenses: December 31, 2018 2017 Employees and payroll accruals $ 16,717 $ 13,283 Taxes payable and others 12,263 9,110 Provision for settlement (Note 12) - 5,500 Deferred revenues 8,840 4,959 Other 32 144 $ 37,852 $ 32,996 |
Employee Benefit Obligations
Employee Benefit Obligations | 12 Months Ended |
Dec. 31, 2018 | |
Compensation And Retirement Disclosure [Abstract] | |
Employee Benefit Obligations | Note 9: Employee benefit obligations The Company sponsors a defined benefit plan (the “Swiss Plan”) for all its employees in Switzerland for retirement benefits, as well as benefits on death or long-term disability. The liability in respect of the Swiss Plan is the projected benefit obligation calculated using the projected unit credit method. The projected benefit obligation as of December 31, 2018 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee service rendered before that date. Swiss Plan assets are recorded at fair value. Pension expense is presented in the payroll expenses in the various functions in which the employees are engaged. Actuarial gains and losses arising from differences between the actual and the expected return on the Swiss Plan assets are recognized in accumulated other comprehensive income (loss) and amortized over the requisite service period. The Swiss Plan is part of a collective pension foundation managed by a top tier insurance company. The Company’s exposure under the Swiss Plan is insured. The Company has financial exposure under the Swiss Plan only in the event that the insurance company does not meet its obligations. The Company and the employees pay retirement contributions, which are defined as a percentage of the employees’ covered salaries. Interest is credited to the employees’ account at the minimum rate provided in the Swiss Plan, which represents the Swiss Plan’s primary asset. The targeted allocation for these funds is as follows: Asset Allocation by Category as of December 31, 2018: Asset Category: Asset allocation (%) Debt Securities 28 Real Estate 22 Equity Securities 28 Others 22 Total 100 The following table sets forth the Swiss Plan’s funded status and amounts recognized in the consolidated financial statements for the year ended December 31, 2018 and 2017: December 31, 2018 2017 Change in Benefit Obligation Projected benefit obligation at beginning of year $ 10,317 $ 8,241 Interest cost 64 54 Company service cost 820 878 Employee contributions 486 417 Prior service cost - (314 ) Benefits paid 475 341 Actuarial loss 87 700 Projected benefit obligation at end of year $ 12,249 $ 10,317 Change in Plan Assets Fair value of plan assets at beginning of year $ 8,243 $ 5,978 Actual return on plan assets 3 882 Employer contributions 729 625 Employee contributions 486 417 Benefits paid 475 341 Fair value of plan assets at end of year $ 9,936 $ 8,243 Funded Status at End of year Excess of obligation over assets $ (2,313 ) $ (2,074 ) Change in Accrued Benefit Liability Accrued benefit liability at beginning of year $ (2,074 ) $ (2,263 ) Company contributions made during year 729 625 Net periodic benefit cost for year (874 ) (1,036 ) Net decrease (increase) in accumulated other comprehensive loss (94 ) 600 Accrued benefit liability at end of year $ (2,313 ) $ (2,074 ) December 31, 2018 2017 Non - current plan assets $ 9,936 $ 8,243 Non - current liability 12,249 10,317 Accrued benefit liability at end of year $ (2,313 ) $ (2,074 ) Projected Benefit Payments Projected year 1 $ 206 $ 166 Projected year 2 205 168 Projected year 3 1,158 172 Projected year 4 195 1,124 Projected year 5 200 163 Projected year 6-10 $ 2,859 $ 1,053 The fair value of the plan assets is the estimated cash surrender value of the insurance contract at December 31, 2018. The level of inputs used to measure fair value was Level 2. Year ended December 31, 2018 2017 Net Periodic Benefit Cost Service cost $ 820 $ 878 Interest cost (income) 69 62 Expected return on plan assets (54 ) (42 ) Amortization of prior service costs 65 124 Amortization of transition obligation (18 ) 14 Total net periodic benefit cost $ 882 $ 1,036 Weighted average assumptions: Discount rate as of December 31 0.90% 0.60% Expected long-term rate of return on assets 0.90% 0.60% Rate of compensation increase 1.00% 1.00% Mortality and disability assumptions BVG 2015 GT BVG 2015 GT (*) Mortality data used for actuarial calculation. |
Long-Term Loan, Net of Discount
Long-Term Loan, Net of Discount and Issuance Costs | 12 Months Ended |
Dec. 31, 2018 | |
Debt Disclosure [Abstract] | |
Long-Term Loan, Net of Discount and Issuance Costs | Note 10: Long-term loan, net of discount and issuance costs On February 7, 2018, the Company and certain of its subsidiaries entered into a Loan and Security Agreement (“2018 Loan Agreement”) with BioPharma Credit PLC pursuant to which such lender made a term loan to the Company in the principal amount of $150 million (the “2018 Credit Facility”). The term loan, which was drawn in full upon execution of the 2018 Loan Agreement, bears interest at 9.0% per annum, payable quarterly in arrears. The Company used a portion of the proceeds of the 2018 Credit Facility to repay in full the Company’s obligations under its then-existing term loan credit facility and is using the remaining proceeds to fund general corporate purposes. The 2018 Credit Facility will mature on February 7, 2023, at which time any unpaid principal and accrued unpaid interest in respect of the term loan will be due and payable. The Company may prepay the term loan, in full, at any time. The Company must prepay the term loan (i) in full or in part upon the entry into certain licensing arrangements and (ii) in full in the event of a change of control. In each case, any prepayment (whether permitted or mandatory) is subject to a prepayment premium and/or make-whole payment. The pre-payment fee if the Company prepays outstanding loan amounts prior to February 7, 2021 is 2.0% and is 1.0% if made after the February 7, 2021 but prior to February 7, 2022. All obligations under the 2018 Credit Facility are guaranteed by the Company’s current and future direct and indirect subsidiaries. In addition, the obligations under the 2018 Credit Facility are secured by a first-priority security interest in substantially all of the property and assets of, as well as the equity interests owned by, the Company and certain of the other guarantors. The 2018 Credit Facility contains other customary covenants. Total net issuance costs of the 2018 Credit Facility, which were $ 731 December On February 7, 2018, the Company’s 2015 term loan credit facility |
Other Long-term Liabilities
Other Long-term Liabilities | 12 Months Ended |
Dec. 31, 2018 | |
Other Liabilities Disclosure [Abstract] | |
Other Long-term Liabilities | Note 11: Other long-term liabilities December 31, 2018 2017 Deferred rent liability $ 773 $ 746 Leasehold improvements financing and other (see a and b below) 94 128 Unrecognized tax benefits (Note 13e) 103 244 Deferred tax liability 124 - Term Loan Credit Facility repayment fee (Note 10) - 619 $ 1,094 $ 1,737 (1). In July 2013, the Company entered into a loan agreement with the landlord of its facility in Switzerland whereby the landlord will offer a loan of up to CHF 400 for the purpose of financing leasehold improvements in the facility. As of December 31, 2018 and 2017, the Company received CHF 220 ($232) of this financing. The principal and interest is due in monthly payments from January 1, 2014 through December 31, 2018 and bears an annual interest of 5%. As of December 31, 2018, the loan was fully repaid. (2). In May 2013, the Company entered into an agreement with the landlord of one of its facilities in the United States and in January 2014, the Company entered into an agreement with a leasing company for an aggregate of $226 for the purpose of financing leasehold improvements in the facility and a lease of machinery, respectively. The loan and interest is due in monthly payments from June 1, 2013 through May 1, 2023 and bears an annual interest of 7%. The above principal leasehold improvement financing repayments as of December 31, 2018 are as follows: 2019 $ 31 2020 29 2021 26 2022 27 2023 12 125 Less: current portion of long-term loans (31 ) Long-term loans, net of current portion $ 94 |
Commitments and Contingent Liab
Commitments and Contingent Liabilities | 12 Months Ended |
Dec. 31, 2018 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments and Contingent Liabilities | Note 12: Commitments and contingent liabilities a. Operating Leases. The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2024. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2021. Future minimum lease payments under non-cancelable operating leases as of December 31, 2018, are as follows: 2019 $ 3,807 2020 3,053 2021 2,549 2022 2,282 2023 1,530 Thereafter 323 $ 13,544 Lease and rental expense for the years ended December 31, 2018, 2017 and 2016 was $4,033, $3,474, and $2,748, respectively. As of December 31, 2018 and 2017 the Company pledged bank deposits of $1,143 and $1,038, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained guarantees by the bank for the fulfillment of the Company’s lease commitments of $1,299 and $1,202, respectively. b. Technion Settlement Agreement In the first quarter of 2018, the Company made the final milestone payment of $5.5 million (the “Milestone Payment”) to the Technion Research and Development Foundation (“Technion”) pursuant to the settlement agreement dated February 10, 2015 (the “Settlement Agreement”). Pursuant to the Settlement Agreement, and in exchange for a release of potential disputes regarding intellectual property developed by our founder and previously assigned to us, c. Zai License and Collaboration Agreement On September 10, 2018, the Company entered into a License and Collaboration Agreement (the “Zai Agreement”) with Zai Lab (Shanghai) Co., Ltd. (“Zai”). Under the Zai Agreement, the Company granted Zai exclusive rights to commercialize Optune in the field of oncology in China, Hong Kong, Macau and Taiwan (“Greater China”). The Zai Agreement also established a development partnership for Optune in multiple solid tumor indications. In partial consideration for the license grant to Zai for Greater China, the Company was entitled to a non-refundable, up-front license fee in the amount of $15 million (the “License Fee”). The Agreement also provides for certain development, regulatory and commercial milestone payments totaling up to $78 million. Furthermore, pursuant to the Agreement Zai will pay the Company tiered royalties at percentage rates from 10 up to the mid-teens on the net sales of the licensed products in Greater China. Zai is purchasing licensed products for commercial use exclusively from the Company at the Company’s fully burdened manufacturing cost. Zai paid the License Fee in the fourth quarter of 2018. Net of withholding taxes, the Company received $12.7 million. The Company recognizes revenue pursuant to the License Agreement with Zai in accordance with ASC 606, "Revenue Recognition from Customers". The License Fee, net of withholding taxes, is deferred and recognized over related six year performance period. The License Fee will be recognized on a straight-line basis, resulting in revenue of $767 for the year ended December 31, 2018. The deferred portion of the License Fee is presented in the balance sheet as deferred revenues, under Other Payables and Accrued Expenses and Long-term Liabilities, respectively. Revenue from any future milestone payments will be recognized upon the achievement of such milestones, in accordance with ASC 606, “Gain Contingencies". Revenue from any future royalty payments will be recognized in accordance with ASC 606. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 13: Income taxes a. Tax provision The provision (benefit) for income taxes from continuing operations is comprised of: Income (loss) before income taxes: Year ended December 31, 2018 2017 2016 United States (U.S.) $ (114,890 ) $ (77,654 ) $ (80,972 ) Non-U.S. 68,948 29,157 (40,492 ) $ (45,942 ) $ (48,497 ) $ (121,464 ) Income taxes expense (benefit): Year ended December 31, 2018 2017 2016 Current: U.S. $ 6,701 $ 8,491 $ 6,501 Non-U.S. 10,568 5,028 3,863 Total current 17,269 13,519 10,364 Deferred: U.S. $ - $ (3 ) $ 1 Non-U.S. 348 (351 ) 16 Total deferred 348 (354 ) 17 Total income taxes provision $ 17,617 $ 13,165 $ 10,381 b. Theoretical tax For purposes of comparability, the Company used the notional U.S. federal income tax rate of 21% for the 2018 tax year and 35% for the 2017 and 2016 tax years when presenting the Company's reconciliation of the income tax provision. The Company is a resident taxpayer in Jersey and as such is not generally subject to Jersey tax on remitted foreign earnings. A reconciliation of the provision for income taxes compared with the amounts at the notional federal statutory rate was: Year ended December 31, 2018 2017 2016 U.S statutory income taxes rate 21.0 % 35.0 % 35.0 % Non-deductible expenses (2.2 ) (6.8 ) (2.5 ) Foreign taxes rate differential 13.2 15.1 (14.2 ) Change in valuation allowance (1) (62.3 ) (11.9 ) (30.0 ) State income taxes (1) (4.5 ) 18.7 2.3 Share based compensation (4.5 ) (4.5 ) 1.2 Change in unrecognized taxes expense 0.3 (0.8 ) (0.7 ) Other (1) 0.7 (71.9 ) 0.4 Effective taxes rate (38.3 )% (27.1 )% (8.5 )% _____________________________ (1) For additional information, see the table below reflecting the net impact of the TCJA. The Company's tax rate is affected by the tax rates in the jurisdictions outside the U.S. in which the Company operates. The jurisdictional location of earnings is a significant component of our effective tax rate as the tax rates outside of the U.S. generally differ from the U.S. tax rate of 21% for the 2018 tax year and 35% for the 2017 and 2016 tax years, and the relative amount of losses or income for which no tax benefit or expense was recognized due to a valuation allowance . In 2017, the Tax Cuts and Jobs Act of 2017 (the “TCJA”) was signed into law in the U.S. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017. In accordance with ASC 740, the Company recorded $34.8 million of deferred tax expense in connection with the remeasurement of certain deferred tax assets and liabilities. This was fully offset by a valuation allowance. Accordingly, there was no net impact on the Company’s income tax expense for the year ended December 31, 2017. The Company’s subsidiary in the United States does not have any foreign subsidiaries and, therefore, the remaining provisions of the TCJA have no material impact on the Company's results of operations. December 22, 2018 marked the end of the measurement period for purposes of SAB 118, and the Company concluded that no change was required to its initial assessment. The table below reflects the net impact of the TCJA: Year ended December 31, 2017 ETR before TCJA US Tax Cuts & Jobs Act Impact Reported ETR U.S statutory income taxes rate 35.0 % 0.0 % 35.0 % Non-deductible expenses (6.8 ) 0.0 (6.8 ) Foreign taxes rate differential 15.1 0.0 15.1 Change in valuation allowance (83.4 ) 71.5 (11.9 ) State income taxes 12.8 5.9 18.7 Share based compensation 2.0 (6.5 ) (4.5 ) Change in unrecognized taxes expense (0.9 ) 0.1 (0.8 ) Other (0.9 ) (71.0 ) (71.9 ) Effective taxes rate (27.1 )% 0.0 % (27.1 )% c. Deferred income tax Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2018 2017 Deferred tax assets: Allowance for doubtful accounts $ - $ 6,797 Revenue recognition 99,316 60,099 Net operating loss carryforwards 843 972 Share based compensation 10,886 7,544 Deferred revenue 1,643 1,340 Other temporary differences 1,384 1,147 Total gross deferred taxes assets $ 114,072 $ 77,899 Less: valuation allowance (112,360 ) (75,804 ) Total deferred taxes assets $ 1,712 $ 2,095 Deferred tax liabilities: Fixed assets 1,427 1,486 Total gross deferred taxes liabilities $ 1,427 $ 1,486 Net deferred taxes assets $ 285 $ 609 d. Carryforward loss: As of December 31, 2018, the Company has $3.2 million of net operating loss carry forwards (NOLs) available for utilization in Luxembourg in future years. e. Uncertain tax benefits: A reconciliation of the beginning and ending balances of uncertain tax benefits is as follows: December 31, 2018 2017 2016 Balance at beginning of the year $ 2,827 $ 2,400 $ 1,565 Additions (reductions) for taxes positions related current year (141 ) 55 1,088 Additions (reductions) for taxes positions related to prior years (2,583 ) 372 58 Additions (reductions) related to lapse of applicable statute of limitations - - (311 ) Balance at the end of the year $ 103 $ 2,827 $ 2,400 The Company recognizes interest and penalties related to unrecognized tax benefits in tax expense. During the years ended December 31, 2018, 2017 and 2016, the Company accrued $2, $ The Company's Israeli subsidiary concluded a federal income tax audit for the tax year 2013-2016. There are no other ongoing income tax audits. |
Share Capital
Share Capital | 12 Months Ended |
Dec. 31, 2018 | |
Share Based Compensation Allocation And Classification In Financial Statements [Abstract] | |
Share Capital | Note 14: Share capital Share capital is composed as follows: Issued and outstanding Number of shares December 31, 2018 2017 Ordinary shares no par value 93,254,185 89,478,032 a. Warrants: As part of the Series D and E Convertible Preferred share investment agreements, the investors received warrants to purchase ordinary shares. The Company accounted for these warrants as equity instruments based on the guidance of ASC 815, “Derivatives and Hedging”, ASC 480-10, “Distinguishing Liabilities from Equity”, its related FASB staff positions, ASC 815-40 “Contracts in Entity’s Own Stock” and the AICPA Technical Practice Aid for accounting for preferred shares and warrants, including the roadmap for accounting for freestanding financial instruments indexed to, and potentially settled in, a company’s own stock. Significant terms of the warrants to purchase ordinary shares that were issued to purchasers of the Series D and E Convertible Preferred shares are as follows as of December 31, 2018 and 2017: Warrants for ordinary shares December 31, Exercise price Expiration date 2018 2017 per share January 22, 2018 - 203,241 $ 3.59 July 21, 2018 - 304,863 $ 3.59 - 508,104 In the years ended December 31, 2018 and 2017, warrants to purchase 504,225 and 1,418,711 ordinary shares, respectively, were cashlessly exercised, resulting in the issuance of 437,081 and 803,138 ordinary shares, respectively. Also, in the year ended December 31, 2018 and 2017 warrants to purchase 3,879 and 6,498 ordinary shares, respectively, with an exercise price of $3.59 per share were exercised for cash. Pursuant to a credit facility that the Company entered into in January 2013 (the “Credit Agreement”) which was fully paid in December 2013, the Company issued to the lenders under the Credit Agreement 975,644 warrants to purchase Series H Convertible Preferred shares at an exercise price of $18.77 per share. The warrants were exercised on a cashless basis in January 2016, resulting in the issuance of 315,155 ordinary shares. b. Share option plans and ESPP: Until the IPO in October 2015, the Company maintained and granted option awards under the 2003 Share Option Plan (the “2003 Plan”) and the 2013 Equity Incentive Share Option Plan (the “2013 Plan”) In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). The Company’s shareholders approved the 2015 Plan in September 2015. Under the 2015 Plan, the Company can issue various types of equity compensation awards such as restricted shares, performance shares, restricted stock units (“RSUs”), performance units, long-term cash award and other share-based awards. The options granted generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are cancelled or forfeited before expiration become available for future grants. RSUs granted under the 2015 Plan vest in equal installments over a three-year period. On December 31, 2018, in accordance with the terms of the 2015 Plan, the number of shares available for issuance under the 2015 Plan automatically increased by 4% of the Company’s outstanding ordinary shares as of December 30, 2018. As a result, the number of shares available for issuance under the 2015 Plan increased from 23,307,208 shares to 27,035,515 shares. As of December 31, 2018, 13,843,105 ordinary shares are available for grant under the 2015 Plan. In September 2015, the Company adopted an ESPP to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. The ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Code and the provisions of the ESPP will be construed in a manner consistent with the requirements of such section. The Company began its offerings under the ESPP on August 1, 2016. The Company issued 347,193 ordinary shares for the plan periods ended through December 31, 2018. On December 31, 2018, in accordance with the terms of the ESPP, the number of shares available for The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model, with the following underlying assumptions: Year ended December 31, 2018 2017 2016 Stock Option Plans Expected term (years) 5.50-6.25 5.50-6.25 6.25 Expected volatility 52%-55% 57%-59% 58%-62% Risk-free interest rate 2.70%-2.99% 1.97%-2.23% 1.23%-1.88% Dividend yield 0.00% 0.00% 0.00% ESPP Expected term (years) 0.50 0.50 0.42 Expected volatility 45%-53% 76%-82% 70% Risk-free interest rate 1.61%-2.14% 0.62%-1.13% 0.4% Dividend yield 0.00% 0.00% 0.00% A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2018 and changes during the year ended on that date is presented below: Year ended December 31, 2018 Number of options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of year 14,806,027 $ 10.64 Granted 2,520,502 $ 23.73 Exercised (2,693,236 ) $ 6.89 Forfeited and cancelled (195,078 ) $ 15.09 Outstanding at end of year 14,438,215 $ 13.56 $ 287,706 Exercisable options 6,090,628 $ 11.04 $ 136,695 A summary of the status of the Company’s RSUs as of December 31, 2018 and changes during the year ended on that date is presented below: Year ended December 31, 2018 Number of RSUs Weighted average grant date fair value price Aggregate intrinsic value Unvested at beginning of year $ 1,651,219 $ 9.66 Granted 535,220 23.32 Vested (556,563 ) 9.90 Forfeited and cancelled (16,679 ) 15.79 Unvested at end of year 1,613,197 $ 14.04 $ 54,010 The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the years ended December 31, 2018, 2017 and 2016, was comprised as follows: Year ended December 31, 2018 2017 2016 Cost of revenues $ 1,261 $ 467 $ 623 Research, development and clinical trials 4,709 3,587 3,155 Sales and marketing 7,393 3,784 5,111 General and administrative 26,483 19,278 12,552 Total share-based compensation expense $ 39,846 $ 27,116 $ 21,441 As of December 31, 2018, there were unrecognized compensation costs of $43,315, which are expected to be recognized over a weighted average period of approximately 2.60 years. The weighted average grant date exercise price of the Company’s options granted during the years ended December 31, 2018, 2017 and 2016 were $23.73, $10.53 and $7.37 per share, respectively. The weighted average grant date fair values of the Company’s options forfeited and cancelled during the years ended December 31, 2018, 2017 and 2016 were $15.09, $12.54 and $9.72, respectively. The aggregate intrinsic values for the options exercised during the years ended December 31, 2018, 2017 and 2016 were $57,813, $17,945 and $7,637, respectively. The aggregate intrinsic value is calculated as the difference between the per share exercise price and the deemed fair value of the Company’s ordinary shares for each share subject to an option multiplied by the number of shares subject to options at the date of exercise. The Company deemed the fair value of the Company’s ordinary shares to be $33.48, $20.20 and $7.85 per share as of December 31, 2018, 2017, and 2016, respectively. The options outstanding as of December 31, 2018 are as follows: Exercise price Number of options outstanding Weighted average remaining contractual term Number of options exercisable Weighted average remaining contractual term $ (years) (years) 0.23 - 1.00 46,045 1.28 46,045 1.28 1.01 - 7.00 1,741,728 3.43 1,664,228 3.23 7.01 - 11.00 3,358,859 7.16 1,477,492 5.91 11.01 - 16.00 4,725,204 7.43 1,745,554 6.76 16.01 - 20.00 298,637 8.57 71,502 8.57 20.01 - 27.50 3,661,651 8.57 1,073,462 6.98 27.51 - 35.00 606,091 9.53 12,345 9.42 14,438,215 7.27 6,090,628 5.61 |
Financial Expenses, Net
Financial Expenses, Net | 12 Months Ended |
Dec. 31, 2018 | |
Interest And Debt Expense [Abstract] | |
Financial Expenses, Net | Note 15: Financial expenses, net The following table sets forth the Company’s total financial expenses, net: Year ended December 31, 2018 2017 2016 Financial expenses: Interest expense $ (13,491 ) $ (10,261 ) $ (5,937 ) Amortization of credit facility costs (2,777 ) (1,111 ) (667 ) Foreign currency transaction losses (398 ) - (396 ) Others (242 ) (321 ) (318 ) $ (16,908 ) $ (11,693 ) $ (7,318 ) Financial income: Amortization of treasury bills premium $ 1,986 $ 859 $ 512 Foreign currency transaction gains - 549 - Interest income 2,652 1,116 659 $ 4,638 $ 2,524 $ 1,171 Total financial expenses, net $ (12,270 ) $ (9,169 ) $ (6,147 ) |
Basic and Diluted Net Loss Per
Basic and Diluted Net Loss Per Share | 12 Months Ended |
Dec. 31, 2018 | |
Earnings Per Share [Abstract] | |
Basic and Diluted Net Loss Per Share | Note 16: Basic and diluted net loss per share The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share: Year ended December 31, 2018 2017 2016 Net income (loss) attributable to ordinary shares as reported $ (63,559 ) $ (61,662 ) $ (131,845 ) Shares used in computing net income (loss) per ordinary share, basic and diluted 91,828,043 88,546,719 85,558,448 Net income (loss) per ordinary share, basic and diluted $ (0.69 ) $ (0.70 ) $ (1.54 ) For the years ended December 31, 2018, 2017 and 2016, all outstanding preferred shares, options and warrants have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive. |
Subcontractor
Subcontractor | 12 Months Ended |
Dec. 31, 2018 | |
Subcontractor [Abstract] | |
Subcontractor | In certain markets and for certain key components, the Company is currently dependent upon sole source suppliers used in its delivery systems. The Company’s management believes that in most cases other suppliers could provide similar components at comparable terms. A change of suppliers which requires FDA or other regulatory approval, however, could cause a material delay in manufacturing and a possible loss of sales, which could adversely affect the Company’s operating results and financial position. |
Supplemental Information
Supplemental Information | 12 Months Ended |
Dec. 31, 2018 | |
Geographic Areas Long Lived Assets [Abstract] | |
Supplemental Information | Note 18: Supplemental information The following table presents long-lived assets by location: December 31, 2018 2017 2016 United States $ 8,289 $ 10,372 $ 11,981 Switzerland 2,513 5,114 4,346 Israel 2,236 2,081 1,915 Germany 1,054 190 49 Others 1,274 310 329 $ 15,366 $ 18,067 $ 18,620 The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows: Year ended December 31, 2018 2017 2016 United States $ 168,414 $ 134,688 $ 72,771 EMEA (*) 73,304 42,035 10,028 Japan 6,351 303 89 $ 248,069 $ 177,026 $ 82,888 (*) including Germany $ 67,849 $ 40,215 $ 9,799 |
Selected Quarterly Financial In
Selected Quarterly Financial Information (Unaudited) | 12 Months Ended |
Dec. 31, 2018 | |
Selected Quarterly Financial Information [Abstract] | |
Selected Quarterly Financial Information (Unaudited) | Note 19: Selected quarterly financial information (Unaudited) The following table sets forth selected financial information for the Company: 2018 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 69,674 $ 64,756 $ 61,514 $ 52,125 Gross profit $ 46,646 $ 45,807 $ 41,681 $ 33,887 Operating income (loss) $ (8,664 ) $ (5,246 ) $ (7,085 ) $ (12,677 ) Net income (loss) $ (15,631 ) $ (11,694 ) $ (15,510 ) $ (20,724 ) Basic and diluted net income (loss) per ordinary share $ (0.17 ) $ (0.13 ) $ (0.17 ) $ (0.23 ) Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share 93,083,298 92,911,375 91,331,862 89,985,612 2017 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 53,661 $ 50,109 $ 38,376 $ 34,880 Gross profit $ 38,021 $ 34,956 $ 25,224 $ 23,216 Operating income (loss) $ (4,506 ) $ (5,919 ) $ (15,530 ) $ (13,373 ) Net income (loss) $ (10,945 ) $ (11,498 ) $ (21,174 ) $ (18,045 ) Basic and diluted net income (loss) per ordinary share $ (0.12 ) $ (0.13 ) $ (0.24 ) $ (0.21 ) Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share 89,389,364 89,125,646 88,218,868 87,452,983 2016 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 30,242 $ 21,674 $ 17,919 $ 13,053 Gross profit $ 19,268 $ 10,556 $ 1,710 $ 5,071 Operating income (loss) $ (17,877 ) $ (28,265 ) $ (37,237 ) $ (31,938 ) Net income (loss) $ (22,168 ) $ (33,628 ) $ (40,612 ) $ (35,437 ) Basic and diluted net income (loss) per ordinary share $ (0.26 ) $ (0.39 ) $ (0.48 ) $ (0.42 ) Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share 86,760,316 85,774,874 85,274,683 84,397,164 |
Subsequent Event
Subsequent Event | 12 Months Ended |
Dec. 31, 2018 | |
Subsequent Events [Abstract] | |
Subsequent Event | Note 20: Subsequent Event. The Company has been informed that, on February 3, 2019, a civil claim was filed in the District Court in Haifa, Israel, by Ofir Paz (“Paz”), a former member of the Company’s Board of Directors, and EES Investments Ltd., a company wholly owned by Paz (together with Paz, “Plaintiff”) against the Company and Prof. Yoram Palti. Plaintiff claims that he is entitled to 210,000 ordinary shares pursuant to an alleged 2003 verbal agreement between Plaintiff and Prof. Palti, who was also a member of the Company’s Board of Directors at that time, for Plaintiff’s contribution to the advancement of the Company’s business and the consummation of a third party investment in the Company. Plaintiff is asking the court to issue an order (i) providing that he is the holder of 210,000 ordinary shares of the Company, or alternatively (ii) providing that he is entitled to receive from the Company and Prof. Palti 210,000 shares of the Company, and (iii) ordering that the Company’s register of shareholders be amended to reflect his ownership of such shares. To date, the claim has not been duly served with us. We believe that the complaint is without merit and plans to defend against this claim vigorously. We have not accrued any amounts in respect of these claims, as a liability is not probable and the amount of any potential liability cannot be reasonably estimated. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2018 | |
Significant Accounting Policies [Line Items] | |
Use of Estimates | a. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, tax liabilities, useful-life of field equipment, revenue recognition and the estimations required in accrual base accounting, and share-based compensation costs. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting period. Actual results could differ from those estimates. |
Financial Statements in U.S. Dollars | b. Financial statements in U.S. dollars: The accompanying financial statements have been prepared in U.S. dollars in thousands, except for share and per-share data. The Company finances its operations in U.S. dollars and a substantial portion of its costs and revenues from its primary markets is incurred in U.S. dollars. As such, the Company’s management believes that the U.S. dollar is the currency of the primary economic environment in which NovoCure Limited and certain subsidiaries operate. The Company’s reporting currency is U.S. dollars. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the U.S. dollar are re-measured into dollars in accordance with Accounting Standards Codification (ASC) No. 830-10, “Foreign Currency Matters.” All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as appropriate. For a subsidiary whose functional currency has been determined to be its local currency, assets and liabilities are translated at year-end exchange rates and statement of operations items are translated at average exchange rates prevailing during the year. Such translation adjustments are recorded as a separate component of accumulated other comprehensive income (loss) in shareholders' equity. |
Principles of Consolidation | c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances, including profits from intercompany sales not yet realized outside the Company, have been eliminated upon consolidation. |
Cash Equivalents | d. Cash equivalents: Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less at the date acquired. |
Short-term Investments and Restricted Cash | e. Short-term investments and restricted cash: 1. Short-term investments: The Company accounts for investments in debt securities in accordance with ASC 320, “Investments-Debt and Equity Securities.” Management determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. For the years ended December 31, 2018 and 2017, all securities are classified as held-to-maturity since the Company has the intent and ability to hold the securities to maturity and, accordingly, debt securities are stated at amortized cost. The amortized cost of held-to-maturity securities is adjusted for amortization of premiums and accretion of discounts to maturity and any other than temporary impairment losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate. For the three years ended December 31, 2018, no impairment losses have been identified. 2. Restricted cash: The Company has restricted cash used as security for the use of Company credit cards, presented in short-term assets. Additionally, the Company has pledged bank deposits to cover bank guarantees related to facility rental agreements, fleet lease agreements and customs payments presented in other long-term assets (see Note 12). |
Trade Receivables | f. Trade receivables: The Company’s trade receivables balance contains billed and unbilled commercial activities. As needed, the Company records an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. The Company periodically reviews its customers’ credit risk and payment history. To date, the Company has not experienced any credit losses related to counter-party risk. |
Inventories | g. Inventories: Inventories are stated at the lower of cost or net realizable value. Cost is determined using the weighted average method. The Company regularly evaluates its ability to realize the value of inventory. If the inventories are deemed damaged, if actual demand for the Company’s delivery systems deteriorates, or if market conditions are less favorable than those projected, inventory write-offs may be required. Inventory write-offs of $684, $489 and $774, respectively, were recorded for the years ended December 31, 2018, 2017 and 2016. |
Property and Equipment | h. Property and equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life |
Impairment of Long-Lived Assets | j. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360-10, “Property, Plant and Equipment,” whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. During the three years ended December 31, 2018, no impairment losses have been identified other than the impairment of field equipment described below in Note 7. |
Other Long-Term Assets | k. Other long-term assets: Longterm lease deposits in respect of office rent and vehicles under operating leases and restricted deposits are presented in other long-term assets. |
Revenue Recognition | l. Revenue recognition: Optune is comprised of two main components: (1) an electric field generator and (2) transducer arrays and related accessories. We retain title to the electric field generator, and the patient is provided replacement transducer arrays and technical support for the device during the term of treatment. The electric field generator and transducer arrays are always supplied and function together and are not sold on a standalone basis. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU 2014-09), an updated standard on revenue recognition and issued subsequent amendments to the initial guidance in March 2016, April 2016, May 2016 and December 2016 within ASU 2016-08, 2016-10, 2016-12 and 2016-20, respectively (collectively, “ASC 606”). The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods and services to patients in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. In addition, the new standard requires expanded disclosures for all contracts. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605). The amount of revenue recognized in 2018 reflects the consideration to which the Company expects to be entitled to receive in exchange for Optune. The Company uses the portfolio approach to apply the standard to portfolios of contracts with similar characteristics. To recognize revenue under ASC 606, the Company applies the following five steps: 1. Identify the contract with a patient. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to performance obligations in the contract. 5. Recognize revenue when or as the Company satisfies a performance obligation. At adoption of ASC 606, trade receivables increased by $2,807, deferred revenues increased by $645 and the Company recorded a cumulative impact to its accumulated deficit of $2,162. The impact of the Company’s adoption of ASC 606 compared to ASC 605 on the consolidated statements of income for the three months and year ended December 31, 2018 was as follows: net revenue decreased by $4,054 and $8,683, respectively; net loss increased by $4,136 and $8,679, respectively; and our basic and diluted net loss per ordinary share increased by $0.04 and $0.09, respectively. The impact of the Company’s adoption of ASC 606 compared to ASC 605 on the balance sheet as of December 31, 2018 was a decrease in trade receivables of $6,288, an increase to other payables and accrued expenses (deferred revenues net of tax provision) of $1,052 Deferred revenues include amounts invoiced for days of therapy to be provided in future periods. Unbilled revenues include revenues recognized for therapy provided and not invoiced in the reported period, and are presented as part of accounts receivable. Revenues are presented net of indirect taxes of $1,698, $ 1,239 and $ 972 for the years ended December 31, 2018, 2017 and 2016, respectively. Net revenues in 2018 also include amounts recognized pursuant to the Zai Agreement. For additional information, see Note 12. |
Charity Care | m. Charitable care: The Company provides Optune treatment at no charge to patients who meet certain criteria under its charitable care policy. Because the Company does not pursue collection of amounts determined to qualify as charity, they are not reported as revenue. The Company's costs of care provided under charitable care were $2,762, $1,483 and $ 1,675 for the years ended December 31, 2018, 2017 and 2016, respectively. These amounts were determined by applying charitable care as a percentage of total billings to total cost of goods sold. |
Shipping and Handling Costs | n. Shipping and handling costs: The Company does not separately bill its customers for shipping and handling costs associated with shipping Optune to its customers. These direct shipping and handling costs of $2,936, $5,322 and $3,389 for the years ended December 31, 2018, 2017 and 2016, respectively are included in Sales and Marketing costs. |
Accounting for Share-based Payments | o. Accounting for share-based payments: The Company accounts for share-based compensation in accordance with ASC 718, “Compensation—Stock Compensation.” ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company recognizes compensation costs for the value of awards granted using the accelerated method over the requisite service period of the award, which is generally the restricted share unit vesting term of three years and option vesting term of four years, respectively. The Company selected the Black-Scholes model as the most appropriate fair value method for all equity awards and the Employee Share Purchase Plan (the “ESPP”). For market condition awards, the Company also applied the Monte-Carlo simulation model. The Black-Scholes model requires a number of assumptions, of which the most significant are the share price, expected volatility and the expected equity award term. The computation of expected volatility is based on actual historical share price volatility of comparable companies. Expected term of options granted is calculated using the average between the vesting period and the contractual term to the expected term of the options in effect at the time of grant. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms. In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted ASU 2016-09 during the quarter ended March 31, 2017, at which time it changed its accounting policy to account for forfeitures as they occur. The change was applied on a modified retrospective basis with a cumulative effect adjustment to accumulated deficit of $670 as of January 1, 2017. In addition, excess tax benefits for share-based payments are now presented as an operating activity in the statements of cash flows rather than financing activity. The changes have been applied prospectively in accordance with the ASU and prior periods have not been adjusted. |
Fair Value of Financial Instruments | p. Fair value of financial instruments: The carrying amounts of cash and cash equivalents, short-term investments, restricted cash, receivables and prepaid expenses, trade receivables, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the long-term loans approximate fair value. The Company accounts for certain assets and liabilities at fair value under ASC 820, “Fair Value Measurements and Disclosures.” Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. The three levels of inputs that may be used to measure fair value are as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace, other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets with insufficient volume or infrequent transactions, or other inputs that are observable (model-derived valuations in which significant inputs are observable), or can be derived principally from or corroborated by observable market data; and Level 3 - Unobservable inputs which are supported by little or no market activity. The availability of observable inputs can vary from instrument to instrument and is affected by a wide variety of factors, including, for example, the type of instrument, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the instrument are categorized as Level 3. |
Basic and Diluted Net Loss Per Share | q. Basic and diluted net loss per share: Basic and diluted net loss per share is computed based on the weighted average number of ordinary shares outstanding during each year. Diluted loss per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus dilutive potential shares considered outstanding during the period, in accordance with ASC 260-10. Basic and diluted net loss per ordinary share was the same for each period presented as the inclusion of all potential ordinary shares (all options and warrants) outstanding was anti-dilutive. |
Income Taxes | r. Income taxes: The Company accounts for income taxes in accordance with ASC 740-10, “Income Taxes.” ASC 740-10 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed. The Company established reserves for uncertain tax positions based on the evaluation of whether or not the Company’s uncertain tax position is “more likely than not” to be sustained upon examination. The Company records interest and penalties pertaining to its uncertain tax positions in the financial statements as income tax expense. |
Concentration of Risks | s. Concentration of risks: Our cash, cash equivalents, short-term investments and trade receivables are potentially subject to a concentration of risk. Cash, cash equivalents and short-term investments are invested at top tier financial institutions globally. As such these investments may be in excess of insured limitations or not insured in certain jurisdictions. Generally, these investments may be redeemed upon demand and therefore, bear minimal risk. The Company has no off-balance sheet concentrations of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. In 2018, one payer represented $22,959, or 9%, of net revenues. In 2017, the same payer represented $15,479, or 9%, of net revenues. In 2016, the same payer represented $10,393, or 13%, of net revenues. Credit risk with respect to trade receivables is limited. |
Retirement, Pension and Severance Plans | t. Retirement, pension and severance plans: The Company has a 401(k) retirement savings plan for its U.S. employees. Each eligible employee may elect to contribute a portion of the employee’s compensation to the plan. As of December 31, 2018, the Company has not made any matching contributions to this plan. The Company has a defined benefit plan with a pension fund for its Swiss employees, whereby the employee and the Company contribute to the pension fund. The Company accounts for its obligation, in accordance with ASC 715, "Compensation – Retirement Benefits" (see Note 9). The pension expense for the years ended December 31, 2018, 2017 and, 2016 was $882, $ 1,036 and $529, respectively. Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company contributes to employee pension plans to fund its severance liabilities. According to Section 14 of Israel Severance Pay Law, the Company makes deposits on behalf of its employees with respect to the Company’s severance liability and therefore no obligation is provided for in the financial statements. Severance pay liabilities with respect to employees who are not subject to Section 14, are provided for in the financial statements based upon the number of years of service and the latest monthly salary and the related deposits are recorded as an asset based on the cash surrender value. Severance expense for the years ended December 31, 2018, 2017 and 2016 amounted to $526, $506 and $430, respectively. |
Contingent Liabilities | u. Contingent liabilities: The Company accounts for its contingent liabilities in accordance with ASC 450, “Contingencies.” A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December 31, 2018 and 2017, the Company was not a party to any ligation that could have a material adverse effect on the Company’s business, financial position, results of operations or cash flows. |
Other Comprehensive Income (Loss) | v. Other comprehensive income (loss): The Company accounts for comprehensive income (loss) in accordance with ASC 220, "Comprehensive Income". ASC 220 establishes standards for the reporting and display of comprehensive income (loss) and its components. Comprehensive income (loss) generally represents all changes in shareholders' equity during the period except those resulting from investments by, or distributions to, shareholders. The accumulated other comprehensive income (loss), net of taxes, relates to a pension liability and foreign currency translation adjustments. |
Recently Issued and Adopted Accounting Pronouncement | w. Recently adopted accounting pronouncements: ASC 606 – see Note 2(i). ASC 718 – see Note 2(o). In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively as of the earliest date practicable. The Company adopted the standard effective as of January 1, 2018, and t In November 2016, FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. This standard requires the presentation of the statement of cash flows to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents. The standard is effective for fiscal years and the interim periods within those fiscal years beginning after December 15, 2017. The Company adopted the standard retrospectively to all periods presented effective as of January 1, 2018. In March 2017, FASB issued ASU 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Post-retirement Benefit Cost under FASB ASC Topic 715, Retirement Benefits. Accordingly, as of January 1, 2017, the Company reports the current service cost component of net periodic benefit cost in Compensation and benefits on the Company's Consolidated Statements of Income, and reports the other components of net periodic benefit recovery as a separate line item outside of Operating income on the Company's Consolidated Statements of Income. These changes in presentation do not result in any changes to net income or earnings per share. Details of the components of net periodic benefit costs are provided in Note 9 (Pensions and employees benefit obligations). The ASU also prospectively restricts capitalization of net periodic benefit costs to the current service cost component when applicable. This restriction has no impact on the Company's financial statements, since the Company does not capitalize any portion of service cost. x. Recently issued accounting pronouncements: In February 2016, FASB issued ASU 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company adopted the new standard effective January 1, 2019. While the Company is continuing to assess the potential impacts of ASU 2016-02, the Company estimates that the adoption of ASU 2016-02 will result in the recognition of right-of-use assets and lease liabilities for operating leases of approximately $15,733 on its Consolidated Balance Sheets for operation leases and it does not expect an impact on its consolidated statements of operations or debt. In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2020. The amendments in this update are effective for fiscal years beginning after December 31, 2019, including interim periods within those fiscal years. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements, footnote disclosures and employee benefit plans’ accounting. In August 2018, FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The implementation costs incurred in a hosting arrangement that is a service contract should be presented as a prepaid asset in the balance sheet and expensed over the term of the hosting arrangement to the same line item in the statement of income as the costs related to the hosting fees. The guidance in this ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, and early adoption is permitted including adoption in any interim period. The amendments should be applied either retrospectively or prospectively to all implementation costs incurred after adoption. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements and related disclosures. In August 2018, FASB issued ASU 2018-14—Compensation—Retirement Benefits—Defined Benefit Plans—General (Topic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans. ASU 2018-14 improves disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. This standard is effective for fiscal years ending after December 15, 2020, for public business entities. Early adoption is permitted. An entity should apply the amendments in this ASU on a retrospective basis to all periods presented. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements and related disclosures. |
Field Equipment | |
Significant Accounting Policies [Line Items] | |
Property and Equipment | i. Field equipment: Field equipment is stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the field equipment which was determined to be 18 to 36 months. Field equipment is equipment being utilized under service agreements, and accounted for in accordance with ASC 840 on a monthly basis as an operating lease. The Company records a write-off provision for any excess, lost or damaged equipment when warranted based on an assessment of the equipment. Write-offs for equipment are included in cost of revenues. During the years ended December 31, 2018, 2017 and 2016, write-offs for $350, $ 195 and $6,436, respectively, were recorded (see Note 7). |
Significant Accounting Polici_3
Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Accounting Policies [Abstract] | |
Property and Equipment at Cost Using Straight-Line Method | Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life |
Cash and Cash Equivalents and_2
Cash and Cash Equivalents and Short Term Investments (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Cash Cash Equivalents And Short Term Investments [Abstract] | |
Summary of Cash and Cash Equivalents | a. Cash and cash equivalents: Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. December 31, 2018 2017 Cash $ 9,197 $ 5,522 Money market funds 131,425 73,070 Total cash and cash equivalents $ 140,622 $ 78,592 |
Summary of Amortized Cost And Recorded Basis of T-bills in Short Term Investments | b. Short-term investments The Company invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments. December 31, 2018 2017 Short-term investments $ 105,256 $ 104,719 |
Receivables and Prepaid Expen_2
Receivables and Prepaid Expenses (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Receivables And Prepaid Expenses [Abstract] | |
Schedule of Receivables and Prepaid Expenses | The following table sets forth the Company’s receivables and prepaid expenses: December 31, 2018 2017 Advances to and receivables from suppliers $ 4,565 $ 2,924 Government authorities 6,106 2,006 Prepaid expenses 3,531 2,890 Others 77 285 $ 14,279 $ 8,105 |
Inventories (Tables)
Inventories (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventories | The following table sets forth the Company’s inventories: December 31, 2018 2017 Raw materials $ 870 $ 4,276 Work in process 8,667 8,435 Finished goods 13,018 9,314 $ 22,555 $ 22,025 |
Property and Equipment, Net (Ta
Property and Equipment, Net (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Property Plant And Equipment [Abstract] | |
Schedule of Property and Equipment, Net | The following table sets forth the Company’s property and equipment, net: December 31, 2018 2017 Cost: Computers and laboratory equipment $ 12,220 $ 10,833 Office furniture 2,308 2,303 Production equipment 1,228 1,222 Leasehold improvements 4,192 3,614 Total cost $ 19,948 $ 17,972 Accumulated depreciation and amortization (11,506 ) (8,941 ) Depreciated cost $ 8,442 $ 9,031 |
Field Equipment, Net (Tables)
Field Equipment, Net (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Field Equipment [Abstract] | |
Schedule of Field Equipment, Net | The following table sets forth the Company’s field equipment, net: December 31, 2018 2017 Field equipment $ 17,380 $ 15,020 Accumulated depreciation (10,456 ) (5,984 ) Field equipment, net $ 6,924 $ 9,036 |
Other Payables and Accrued Ex_2
Other Payables and Accrued Expenses (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Payables And Accruals [Abstract] | |
Schedule of Other Payables and Accrued Expenses | The following table sets forth the Company’s other payables and accrued expenses: December 31, 2018 2017 Employees and payroll accruals $ 16,717 $ 13,283 Taxes payable and others 12,263 9,110 Provision for settlement (Note 12) - 5,500 Deferred revenues 8,840 4,959 Other 32 144 $ 37,852 $ 32,996 |
Employee Benefit Obligations (T
Employee Benefit Obligations (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Compensation And Retirement Disclosure [Abstract] | |
Schedule of Targeted Allocation of Plan Assets | The targeted allocation for these funds is as follows: Asset Allocation by Category as of December 31, 2018: Asset Category: Asset allocation (%) Debt Securities 28 Real Estate 22 Equity Securities 28 Others 22 Total 100 |
Schedule of Change in Benefit Obligations | The following table sets forth the Swiss Plan’s funded status and amounts recognized in the consolidated financial statements for the year ended December 31, 2018 and 2017: December 31, 2018 2017 Change in Benefit Obligation Projected benefit obligation at beginning of year $ 10,317 $ 8,241 Interest cost 64 54 Company service cost 820 878 Employee contributions 486 417 Prior service cost - (314 ) Benefits paid 475 341 Actuarial loss 87 700 Projected benefit obligation at end of year $ 12,249 $ 10,317 Change in Plan Assets Fair value of plan assets at beginning of year $ 8,243 $ 5,978 Actual return on plan assets 3 882 Employer contributions 729 625 Employee contributions 486 417 Benefits paid 475 341 Fair value of plan assets at end of year $ 9,936 $ 8,243 Funded Status at End of year Excess of obligation over assets $ (2,313 ) $ (2,074 ) Change in Accrued Benefit Liability Accrued benefit liability at beginning of year $ (2,074 ) $ (2,263 ) Company contributions made during year 729 625 Net periodic benefit cost for year (874 ) (1,036 ) Net decrease (increase) in accumulated other comprehensive loss (94 ) 600 Accrued benefit liability at end of year $ (2,313 ) $ (2,074 ) December 31, 2018 2017 Non - current plan assets $ 9,936 $ 8,243 Non - current liability 12,249 10,317 Accrued benefit liability at end of year $ (2,313 ) $ (2,074 ) Projected Benefit Payments Projected year 1 $ 206 $ 166 Projected year 2 205 168 Projected year 3 1,158 172 Projected year 4 195 1,124 Projected year 5 200 163 Projected year 6-10 $ 2,859 $ 1,053 |
Schedule of Fair Value the Plan Assets | The fair value of the plan assets is the estimated cash surrender value of the insurance contract at December 31, 2018. The level of inputs used to measure fair value was Level 2. Year ended December 31, 2018 2017 Net Periodic Benefit Cost Service cost $ 820 $ 878 Interest cost (income) 69 62 Expected return on plan assets (54 ) (42 ) Amortization of prior service costs 65 124 Amortization of transition obligation (18 ) 14 Total net periodic benefit cost $ 882 $ 1,036 Weighted average assumptions: Discount rate as of December 31 0.90% 0.60% Expected long-term rate of return on assets 0.90% 0.60% Rate of compensation increase 1.00% 1.00% Mortality and disability assumptions BVG 2015 GT BVG 2015 GT (*) Mortality data used for actuarial calculation. |
Other Long-term Liabilities (Ta
Other Long-term Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Other Liabilities Disclosure [Abstract] | |
Schedule of Other Long-term Liabilities | December 31, 2018 2017 Deferred rent liability $ 773 $ 746 Leasehold improvements financing and other (see a and b below) 94 128 Unrecognized tax benefits (Note 13e) 103 244 Deferred tax liability 124 - Term Loan Credit Facility repayment fee (Note 10) - 619 $ 1,094 $ 1,737 |
Schedule of Leasehold Improvement Financing Repayments | The above principal leasehold improvement financing repayments as of December 31, 2018 are as follows: 2019 $ 31 2020 29 2021 26 2022 27 2023 12 125 Less: current portion of long-term loans (31 ) Long-term loans, net of current portion $ 94 |
Commitments and Contingent Li_2
Commitments and Contingent Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Commitments And Contingencies Disclosure [Abstract] | |
Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases | Future minimum lease payments under non-cancelable operating leases as of December 31, 2018, are as follows: 2019 $ 3,807 2020 3,053 2021 2,549 2022 2,282 2023 1,530 Thereafter 323 $ 13,544 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income (Loss) before Income Taxes, Domestic and Foreign | The provision (benefit) for income taxes from continuing operations is comprised of: Income (loss) before income taxes: Year ended December 31, 2018 2017 2016 United States (U.S.) $ (114,890 ) $ (77,654 ) $ (80,972 ) Non-U.S. 68,948 29,157 (40,492 ) $ (45,942 ) $ (48,497 ) $ (121,464 ) |
Schedule of Components of Income Tax Expense (Benefit) | The provision (benefit) for income taxes from continuing operations is comprised of: Income taxes expense (benefit): Year ended December 31, 2018 2017 2016 Current: U.S. $ 6,701 $ 8,491 $ 6,501 Non-U.S. 10,568 5,028 3,863 Total current 17,269 13,519 10,364 Deferred: U.S. $ - $ (3 ) $ 1 Non-U.S. 348 (351 ) 16 Total deferred 348 (354 ) 17 Total income taxes provision $ 17,617 $ 13,165 $ 10,381 |
Reconciliation of Provision for Income Taxes | A reconciliation of the provision for income taxes compared with the amounts at the notional federal statutory rate was: Year ended December 31, 2018 2017 2016 U.S statutory income taxes rate 21.0 % 35.0 % 35.0 % Non-deductible expenses (2.2 ) (6.8 ) (2.5 ) Foreign taxes rate differential 13.2 15.1 (14.2 ) Change in valuation allowance (1) (62.3 ) (11.9 ) (30.0 ) State income taxes (1) (4.5 ) 18.7 2.3 Share based compensation (4.5 ) (4.5 ) 1.2 Change in unrecognized taxes expense 0.3 (0.8 ) (0.7 ) Other (1) 0.7 (71.9 ) 0.4 Effective taxes rate (38.3 )% (27.1 )% (8.5 )% (1) For additional information, see the table below reflecting the net impact of the TCJA. |
Summary of Net Impact of the Tax Cuts and Jobs Act | The table below reflects the net impact of the TCJA: Year ended December 31, 2017 ETR before TCJA US Tax Cuts & Jobs Act Impact Reported ETR U.S statutory income taxes rate 35.0 % 0.0 % 35.0 % Non-deductible expenses (6.8 ) 0.0 (6.8 ) Foreign taxes rate differential 15.1 0.0 15.1 Change in valuation allowance (83.4 ) 71.5 (11.9 ) State income taxes 12.8 5.9 18.7 Share based compensation 2.0 (6.5 ) (4.5 ) Change in unrecognized taxes expense (0.9 ) 0.1 (0.8 ) Other (0.9 ) (71.0 ) (71.9 ) Effective taxes rate (27.1 )% 0.0 % (27.1 )% |
Schedule of Significant Components of Deferred Tax Assets and Liabilities | Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2018 2017 Deferred tax assets: Allowance for doubtful accounts $ - $ 6,797 Revenue recognition 99,316 60,099 Net operating loss carryforwards 843 972 Share based compensation 10,886 7,544 Deferred revenue 1,643 1,340 Other temporary differences 1,384 1,147 Total gross deferred taxes assets $ 114,072 $ 77,899 Less: valuation allowance (112,360 ) (75,804 ) Total deferred taxes assets $ 1,712 $ 2,095 Deferred tax liabilities: Fixed assets 1,427 1,486 Total gross deferred taxes liabilities $ 1,427 $ 1,486 Net deferred taxes assets $ 285 $ 609 |
Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits | A reconciliation of the beginning and ending balances of uncertain tax benefits is as follows: December 31, 2018 2017 2016 Balance at beginning of the year $ 2,827 $ 2,400 $ 1,565 Additions (reductions) for taxes positions related current year (141 ) 55 1,088 Additions (reductions) for taxes positions related to prior years (2,583 ) 372 58 Additions (reductions) related to lapse of applicable statute of limitations - - (311 ) Balance at the end of the year $ 103 $ 2,827 $ 2,400 |
Share Capital (Tables)
Share Capital (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Share Based Compensation Allocation And Classification In Financial Statements [Abstract] | |
Schedule of Share Capital | Share capital is composed as follows: Issued and outstanding Number of shares December 31, 2018 2017 Ordinary shares no par value 93,254,185 89,478,032 |
Schedule of Warrants to Purchase Ordinary Shares were Issued to Purchase of Convertible Preferred Shares | Significant terms of the warrants to purchase ordinary shares that were issued to purchasers of the Series D and E Convertible Preferred shares are as follows as of December 31, 2018 and 2017: Warrants for ordinary shares December 31, Exercise price Expiration date 2018 2017 per share January 22, 2018 - 203,241 $ 3.59 July 21, 2018 - 304,863 $ 3.59 - 508,104 In the years ended December 31, 2018 and 2017, warrants to purchase 504,225 and 1,418,711 ordinary shares, respectively, were cashlessly exercised, resulting in the issuance of 437,081 and 803,138 ordinary shares, respectively. Also, in the year ended December 31, 2018 and 2017 warrants to purchase 3,879 and 6,498 ordinary shares, respectively, with an exercise price of $3.59 per share were exercised for cash. |
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model | The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model, with the following underlying assumptions: Year ended December 31, 2018 2017 2016 Stock Option Plans Expected term (years) 5.50-6.25 5.50-6.25 6.25 Expected volatility 52%-55% 57%-59% 58%-62% Risk-free interest rate 2.70%-2.99% 1.97%-2.23% 1.23%-1.88% Dividend yield 0.00% 0.00% 0.00% ESPP Expected term (years) 0.50 0.50 0.42 Expected volatility 45%-53% 76%-82% 70% Risk-free interest rate 1.61%-2.14% 0.62%-1.13% 0.4% Dividend yield 0.00% 0.00% 0.00% |
Schedule of Stock Options to Purchase Ordinary Shares | A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2018 and changes during the year ended on that date is presented below: Year ended December 31, 2018 Number of options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of year 14,806,027 $ 10.64 Granted 2,520,502 $ 23.73 Exercised (2,693,236 ) $ 6.89 Forfeited and cancelled (195,078 ) $ 15.09 Outstanding at end of year 14,438,215 $ 13.56 $ 287,706 Exercisable options 6,090,628 $ 11.04 $ 136,695 |
Schedule of RSUs | A summary of the status of the Company’s RSUs as of December 31, 2018 and changes during the year ended on that date is presented below: Year ended December 31, 2018 Number of RSUs Weighted average grant date fair value price Aggregate intrinsic value Unvested at beginning of year $ 1,651,219 $ 9.66 Granted 535,220 23.32 Vested (556,563 ) 9.90 Forfeited and cancelled (16,679 ) 15.79 Unvested at end of year 1,613,197 $ 14.04 $ 54,010 |
Schedule of Equity-Based Compensation Expenses Related to Company's Equity-Based Awards | The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the years ended December 31, 2018, 2017 and 2016, was comprised as follows: Year ended December 31, 2018 2017 2016 Cost of revenues $ 1,261 $ 467 $ 623 Research, development and clinical trials 4,709 3,587 3,155 Sales and marketing 7,393 3,784 5,111 General and administrative 26,483 19,278 12,552 Total share-based compensation expense $ 39,846 $ 27,116 $ 21,441 |
Schedule of Stock Option Outstanding | The options outstanding as of December 31, 2018 are as follows: Exercise price Number of options outstanding Weighted average remaining contractual term Number of options exercisable Weighted average remaining contractual term $ (years) (years) 0.23 - 1.00 46,045 1.28 46,045 1.28 1.01 - 7.00 1,741,728 3.43 1,664,228 3.23 7.01 - 11.00 3,358,859 7.16 1,477,492 5.91 11.01 - 16.00 4,725,204 7.43 1,745,554 6.76 16.01 - 20.00 298,637 8.57 71,502 8.57 20.01 - 27.50 3,661,651 8.57 1,073,462 6.98 27.51 - 35.00 606,091 9.53 12,345 9.42 14,438,215 7.27 6,090,628 5.61 |
Financial Expenses, Net (Tables
Financial Expenses, Net (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Interest And Debt Expense [Abstract] | |
Schedule of Financial Expenses, Net | The following table sets forth the Company’s total financial expenses, net Year ended December 31, 2018 2017 2016 Financial expenses: Interest expense $ (13,491 ) $ (10,261 ) $ (5,937 ) Amortization of credit facility costs (2,777 ) (1,111 ) (667 ) Foreign currency transaction losses (398 ) - (396 ) Others (242 ) (321 ) (318 ) $ (16,908 ) $ (11,693 ) $ (7,318 ) Financial income: Amortization of treasury bills premium $ 1,986 $ 859 $ 512 Foreign currency transaction gains - 549 - Interest income 2,652 1,116 659 $ 4,638 $ 2,524 $ 1,171 Total financial expenses, net $ (12,270 ) $ (9,169 ) $ (6,147 ) |
Basic and Diluted Net Loss Pe_2
Basic and Diluted Net Loss Per Share (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Earnings Per Share [Abstract] | |
Schedule of Basic and Diluted Net Loss Per Ordinary Share | The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share: Year ended December 31, 2018 2017 2016 Net income (loss) attributable to ordinary shares as reported $ (63,559 ) $ (61,662 ) $ (131,845 ) Shares used in computing net income (loss) per ordinary share, basic and diluted 91,828,043 88,546,719 85,558,448 Net income (loss) per ordinary share, basic and diluted $ (0.69 ) $ (0.70 ) $ (1.54 ) |
Supplemental Information (Table
Supplemental Information (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Geographic Areas Long Lived Assets [Abstract] | |
Schedule of Long-Lived Assets by Location | The following table presents long-lived assets by location: December 31, 2018 2017 2016 United States $ 8,289 $ 10,372 $ 11,981 Switzerland 2,513 5,114 4,346 Israel 2,236 2,081 1,915 Germany 1,054 190 49 Others 1,274 310 329 $ 15,366 $ 18,067 $ 18,620 |
Schedule of Revenues by Geographic Region | The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows: Year ended December 31, 2018 2017 2016 United States $ 168,414 $ 134,688 $ 72,771 EMEA (*) 73,304 42,035 10,028 Japan 6,351 303 89 $ 248,069 $ 177,026 $ 82,888 (*) including Germany $ 67,849 $ 40,215 $ 9,799 |
Selected Quarterly Financial _2
Selected Quarterly Financial Information (Unaudited) (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Selected Quarterly Financial Information [Abstract] | |
Summary of Selected Quarterly Financial Information (Unaudited) | The following table sets forth selected financial information for the Company 2018 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 69,674 $ 64,756 $ 61,514 $ 52,125 Gross profit $ 46,646 $ 45,807 $ 41,681 $ 33,887 Operating income (loss) $ (8,664 ) $ (5,246 ) $ (7,085 ) $ (12,677 ) Net income (loss) $ (15,631 ) $ (11,694 ) $ (15,510 ) $ (20,724 ) Basic and diluted net income (loss) per ordinary share $ (0.17 ) $ (0.13 ) $ (0.17 ) $ (0.23 ) Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share 93,083,298 92,911,375 91,331,862 89,985,612 2017 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 53,661 $ 50,109 $ 38,376 $ 34,880 Gross profit $ 38,021 $ 34,956 $ 25,224 $ 23,216 Operating income (loss) $ (4,506 ) $ (5,919 ) $ (15,530 ) $ (13,373 ) Net income (loss) $ (10,945 ) $ (11,498 ) $ (21,174 ) $ (18,045 ) Basic and diluted net income (loss) per ordinary share $ (0.12 ) $ (0.13 ) $ (0.24 ) $ (0.21 ) Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share 89,389,364 89,125,646 88,218,868 87,452,983 2016 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 30,242 $ 21,674 $ 17,919 $ 13,053 Gross profit $ 19,268 $ 10,556 $ 1,710 $ 5,071 Operating income (loss) $ (17,877 ) $ (28,265 ) $ (37,237 ) $ (31,938 ) Net income (loss) $ (22,168 ) $ (33,628 ) $ (40,612 ) $ (35,437 ) Basic and diluted net income (loss) per ordinary share $ (0.26 ) $ (0.39 ) $ (0.48 ) $ (0.42 ) Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share 86,760,316 85,774,874 85,274,683 84,397,164 |
Significant Accounting Polici_4
Significant Accounting Policies - Additional Information (Details) - USD ($) | Jan. 01, 2018 | Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2018 | Jan. 01, 2019 |
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Impairment losses on short-term investments | $ 0 | |||||||||||||||||
Inventory write-offs | $ 684,000 | $ 489,000 | $ 774,000 | |||||||||||||||
Impairment of long-lived assets | 0 | |||||||||||||||||
Increase (decrease) in trade receivables | 4,151,000 | 23,228,000 | 6,339,000 | |||||||||||||||
Net revenues | $ 69,674,000 | $ 64,756,000 | $ 61,514,000 | $ 52,125,000 | $ 53,661,000 | $ 50,109,000 | $ 38,376,000 | $ 34,880,000 | $ 30,242,000 | $ 21,674,000 | $ 17,919,000 | $ 13,053,000 | 248,069,000 | 177,026,000 | 82,888,000 | |||
Increase (decrease) in net loss | $ (15,631,000) | $ (11,694,000) | $ (15,510,000) | $ (20,724,000) | $ (10,945,000) | $ (11,498,000) | $ (21,174,000) | $ (18,045,000) | $ (22,168,000) | $ (33,628,000) | $ (40,612,000) | $ (35,437,000) | $ (63,559,000) | $ (61,662,000) | $ (131,845,000) | |||
Increase (decrease) in basic and diluted net loss per ordinary share | $ (0.17) | $ (0.13) | $ (0.17) | $ (0.23) | $ (0.12) | $ (0.13) | $ (0.24) | $ (0.21) | $ (0.26) | $ (0.39) | $ (0.48) | $ (0.42) | $ (0.69) | $ (0.70) | $ (1.54) | |||
Increase in other payables and accrued expenses | $ 4,210,000 | $ 14,460,000 | $ 6,647,000 | |||||||||||||||
Indirect taxes | 1,698,000 | 1,239,000 | 972,000 | |||||||||||||||
Cost related to charitable care | 2,762,000 | 1,483,000 | 1,675,000 | |||||||||||||||
Pension expense | 882,000 | 1,036,000 | 529,000 | |||||||||||||||
Severance costs | 526,000 | 506,000 | 430,000 | |||||||||||||||
Sales Revenue Net | Customer One | Customer Concentration Risk | ||||||||||||||||||
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Net revenues | $ 22,959,000 | $ 15,479,000 | $ 10,393,000 | |||||||||||||||
Concentration risk percentage | 9.00% | 9.00% | 13.00% | |||||||||||||||
Restricted Share Unit | ||||||||||||||||||
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Stock awards granted, vesting period | 3 years | |||||||||||||||||
Option | ||||||||||||||||||
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Stock awards granted, vesting period | 4 years | |||||||||||||||||
Expected dividend yield | 0.00% | 0.00% | 0.00% | |||||||||||||||
Shipping and Handling | ||||||||||||||||||
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Direct costs included in sales and marketing costs | $ 2,936,000 | $ 5,322,000 | $ 3,389,000 | |||||||||||||||
Accounting Standards Update 2014-09 | ||||||||||||||||||
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Increase (decrease) in trade receivables | (6,288,000) | |||||||||||||||||
Cumulative deficit effect adjustment resulting from ASU adoption | $ (6,517,000) | (6,517,000) | $ (6,517,000) | |||||||||||||||
Increase (decrease) in net loss | $ 4,136,000 | $ 8,679,000 | ||||||||||||||||
Increase (decrease) in basic and diluted net loss per ordinary share | $ 0.04 | $ 0.09 | ||||||||||||||||
Increase in other payables and accrued expenses | $ 1,052,000 | |||||||||||||||||
Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606 | ||||||||||||||||||
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Increase (decrease) in trade receivables | $ 2,807,000 | |||||||||||||||||
Increase in deferred revenue | 645,000 | |||||||||||||||||
Cumulative deficit effect adjustment resulting from ASU adoption | $ (2,162,000) | |||||||||||||||||
Net revenues | $ (4,054,000) | $ (8,683,000) | ||||||||||||||||
Accounting Standards Update 2014-09 | First Generation Optune System Field Equipment | ||||||||||||||||||
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Identify the contract with patient | Identify the contract with a patient. A contract with a patient exists when (i) the Company enters into an enforceable contract with a patient that defines each party’s rights regarding delivery of and payment for Optune, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for Optune is probable based on the payer’s intent and ability to pay the promised consideration. The evidence of a contract generally consists of a prescription, a patient service agreement and the verification of the assigned payer for the contract and intention to collect. | |||||||||||||||||
Identify the performance obligations in the contract, description | Optune contracts include the lease of the device, the supply obligation of disposable transducer arrays and technical support for the term of treatment. To the extent a contract includes multiple promised products and/or services, the Company must apply judgment to determine whether those products and/or services are capable of being distinct in the context of the contract. If these criteria are not met the promised products and/or services are accounted for as a combined performance obligation. In the Company’s case, Optune’s device, support, and disposables are provided as one inseparable package of monthly treatment for a single monthly fee. | |||||||||||||||||
Determine the transaction price, description | The transaction price is determined based on the consideration to which the Company will be entitled in exchange for providing Optune to the patient. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. The Company has agreements with many payers that define explicit discounts off the gross transaction price. In addition to the explicit discounts negotiated with each payer, the Company expects to receive, in aggregate for a given portfolio, less than the gross revenue net of explicit discounts. ASC 606 requires that the Company recognize this variable consideration as an implicit discount in the billing period. The implicit discount includes both an estimate of claims that will pay at an amount less than billed and an estimate of claims that will not pay within a given time horizon. The implicit discount adjustments to the transaction price are due to concessions, not collectability concerns driven by payer credit risk. | |||||||||||||||||
Allocate the transaction price to performance obligations in the contract, description | If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. As discussed above, there is a combined performance obligation under the Company’s contracts and, therefore, the monthly transaction price determined for the performance obligation will be recognized over time ratably over the monthly term of the treatment. | |||||||||||||||||
Recognize revenue when or as the company satisfies a performance obligation, description | The Company satisfies performance obligations over time as discussed above. Revenue is recognized at the time the related performance obligation is satisfied by transferring a promised service to a patient. The patient consumes the benefits of Optune treatment on a daily basis over the monthly term. As this criterion is met, the revenues will be recognized over the monthly term. | |||||||||||||||||
Accounting Standards Update 2016-09 | ||||||||||||||||||
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Cumulative deficit effect adjustment resulting from ASU adoption | $ 670,000 | 670,000 | ||||||||||||||||
Accounting Standards Update 2016-02 | Subsequent Event | ||||||||||||||||||
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Operating leases right-of-use assets | $ 15,733,000 | |||||||||||||||||
Operating lease liabilities | $ 15,733,000 | |||||||||||||||||
Field Equipment Under Operating Leases | ||||||||||||||||||
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Equipment write-downs included in cost of revenue | $ 350,000 | $ 195,000 | $ 6,436,000 | |||||||||||||||
Field Equipment Under Operating Leases | Minimum | ||||||||||||||||||
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Property and equipment useful life | 18 months | |||||||||||||||||
Field Equipment Under Operating Leases | Maximum | ||||||||||||||||||
Significant Accounting Policies [Line Items] | ||||||||||||||||||
Property and equipment useful life | 36 months |
Significant Accounting Polici_5
Significant Accounting Policies - Property and Equipment at Cost Using Straight-Line Method (Details) | 12 Months Ended |
Dec. 31, 2018 | |
Computers and laboratory equipment | Minimum | |
Property Plant And Equipment [Line Items] | |
Straight line depreciation rate | 15.00% |
Computers and laboratory equipment | Maximum | |
Property Plant And Equipment [Line Items] | |
Straight line depreciation rate | 33.00% |
Office furniture | Minimum | |
Property Plant And Equipment [Line Items] | |
Straight line depreciation rate | 6.00% |
Office furniture | Maximum | |
Property Plant And Equipment [Line Items] | |
Straight line depreciation rate | 33.00% |
Production equipment | |
Property Plant And Equipment [Line Items] | |
Straight line depreciation rate | 20.00% |
Leasehold improvements | |
Property Plant And Equipment [Line Items] | |
Straight line depreciation useful life | Over the shorter of the term of the lease or its useful life |
Cash and Cash Equivalents and_3
Cash and Cash Equivalents and Short Term Investments - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Cash And Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | $ 140,622 | $ 78,592 |
Cash | ||
Cash And Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 9,197 | 5,522 |
Money market funds | ||
Cash And Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | $ 131,425 | $ 73,070 |
Cash and Cash Equivalents and_4
Cash and Cash Equivalents and Short Term Investments - Summary of Amortized Cost And Recorded Basis of T-bills in Short Term Investments (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Investments Debt And Equity Securities [Abstract] | ||
Short-term investments | $ 105,256 | $ 104,719 |
Cash and Cash Equivalents and_5
Cash and Cash Equivalents and Short Term Investments - Additional Information (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Investments Debt And Equity Securities [Abstract] | ||
Estimated fair value of short-term investments | $ 105,266 | $ 104,655 |
Receivables and Prepaid Expen_3
Receivables and Prepaid Expenses - Schedule of Receivables and Prepaid Expenses (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Receivables And Prepaid Expenses [Abstract] | ||
Advances to and receivables from suppliers | $ 4,565 | $ 2,924 |
Government authorities | 6,106 | 2,006 |
Prepaid expenses | 3,531 | 2,890 |
Others | 77 | 285 |
Receivables and prepaid expenses | $ 14,279 | $ 8,105 |
Inventories - Schedule of Inven
Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 870 | $ 4,276 |
Work in process | 8,667 | 8,435 |
Finished goods | 13,018 | 9,314 |
Total | $ 22,555 | $ 22,025 |
Property and Equipment, Net - S
Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | $ 19,948 | $ 17,972 |
Accumulated depreciation and amortization | (11,506) | (8,941) |
Depreciated cost | 8,442 | 9,031 |
Computers and laboratory equipment | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 12,220 | 10,833 |
Office furniture | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 2,308 | 2,303 |
Production equipment | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 1,228 | 1,222 |
Leasehold improvements | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | $ 4,192 | $ 3,614 |
Property and Equipment, Net - A
Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Property Plant And Equipment [Abstract] | |||
Depreciation expense | $ 1,967 | $ 1,968 | $ 1,673 |
Accumulated computer software capitalized | 6,256 | 5,576 | |
Computer software amortization | $ 1,486 | $ 1,226 |
Field Equipment, Net - Schedule
Field Equipment, Net - Schedule of Field Equipment, Net (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Field Equipment [Abstract] | ||
Field equipment | $ 17,380 | $ 15,020 |
Accumulated depreciation | (10,456) | (5,984) |
Field equipment, net | $ 6,924 | $ 9,036 |
Field Equipment, Net - Addition
Field Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Field Equipment [Line Items] | |||
Depreciation | $ 1,967 | $ 1,968 | $ 1,673 |
Impairment of field equipment | 6,412 | ||
Field equipment | |||
Field Equipment [Line Items] | |||
Depreciation | 5,553 | 4,483 | 3,248 |
Field Equipment Under Operating Leases | |||
Field Equipment [Line Items] | |||
Impairment of field equipment | $ 350 | $ 195 | 6,436 |
First Generation Optune System Field Equipment | Cost of Revenues | |||
Field Equipment [Line Items] | |||
Impairment of field equipment | 6,412 | ||
First Generation Optune System Field Equipment | Cost of Revenues | Finished Goods | |||
Field Equipment [Line Items] | |||
Impairment of field equipment | 4,830 | ||
First Generation Optune System Field Equipment | Cost of Revenues | Production Stage Goods | |||
Field Equipment [Line Items] | |||
Impairment of field equipment | $ 1,582 |
Other Payables and Accrued Ex_3
Other Payables and Accrued Expenses - Schedule of Other Payables and Accrued Expenses (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Payables And Accruals [Abstract] | ||
Employees and payroll accruals | $ 16,717 | $ 13,283 |
Taxes payable and others | 12,263 | 9,110 |
Provision for settlement (Note 12) | 5,500 | |
Deferred revenues | 8,840 | 4,959 |
Other | 32 | 144 |
Other payables and accrued expenses | $ 37,852 | $ 32,996 |
Employee Benefit Obligations -
Employee Benefit Obligations - Schedule of Asset Allocation by Category (Details) | Dec. 31, 2018 |
Defined Benefit Plan Disclosure [Line Items] | |
Target asset allocations | 100.00% |
Debt Securities | |
Defined Benefit Plan Disclosure [Line Items] | |
Target asset allocations | 28.00% |
Real Estate | |
Defined Benefit Plan Disclosure [Line Items] | |
Target asset allocations | 22.00% |
Equity Securities | |
Defined Benefit Plan Disclosure [Line Items] | |
Target asset allocations | 28.00% |
Others | |
Defined Benefit Plan Disclosure [Line Items] | |
Target asset allocations | 22.00% |
Employee Benefit Obligations _2
Employee Benefit Obligations - Net Funded Status (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Change in Benefit Obligation | ||
Projected benefit obligation at beginning of year | $ 10,317 | $ 8,241 |
Interest cost | 64 | 54 |
Company service cost | 820 | 878 |
Employee contributions | 486 | 417 |
Prior service cost | (314) | |
Benefits paid | 475 | 341 |
Actuarial loss | 87 | 700 |
Projected benefit obligation at end of year | 12,249 | 10,317 |
Change in Plan Assets | ||
Fair value of plan assets at beginning of year | 8,243 | 5,978 |
Actual return on plan assets | 3 | 882 |
Employer contributions | 729 | 625 |
Employee contributions | 486 | 417 |
Benefits paid | 475 | 341 |
Fair value of plan assets at end of year | 9,936 | 8,243 |
Funded Status at End of year | ||
Excess of obligation over assets | (2,313) | (2,074) |
Change in Accrued Benefit Liability | ||
Accrued benefit liability at beginning of year | (2,074) | (2,263) |
Company contributions made during year | 729 | 625 |
Net periodic benefit cost for year | (874) | (1,036) |
Net decrease (increase) in accumulated other comprehensive loss | (94) | 600 |
Accrued benefit liability at end of year | (2,313) | (2,074) |
Non - current plan assets | 9,936 | 8,243 |
Non - current liability | 12,249 | 10,317 |
Accrued benefit liability at end of year | (2,313) | (2,074) |
Projected Benefit Payments | ||
Projected year 1 | 206 | 166 |
Projected year 2 | 205 | 168 |
Projected year 3 | 1,158 | 172 |
Projected year 4 | 195 | 1,124 |
Projected year 5 | 200 | 163 |
Projected year 6-10 | $ 2,859 | $ 1,053 |
Employee Benefit Obligations _3
Employee Benefit Obligations - Net Periodic Benefit Cost (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Net Periodic Benefit Cost | ||
Service cost | $ 820 | $ 878 |
Interest cost (income) | 69 | 62 |
Expected return on plan assets | (54) | (42) |
Amortization of prior service costs | 65 | 124 |
Amortization of transition obligation | (18) | 14 |
Total net periodic benefit cost | $ 882 | $ 1,036 |
Weighted average assumptions: | ||
Discount rate as of December 31 | 0.90% | 0.60% |
Expected long-term rate of return on assets | 0.90% | 0.60% |
Rate of compensation increase | 1.00% | 1.00% |
Mortality and disability assumptions | BVG 2015 GT | BVG 2015 GT |
Long-Term Loan, Net of Discou_2
Long-Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) - USD ($) $ in Thousands | Feb. 07, 2018 | Dec. 31, 2018 | Mar. 31, 2018 |
2018 Credit Facility | |||
Line Of Credit Facility [Line Items] | |||
Term loan, principal amount | $ 150,000 | ||
Interest on term loan credit facility | 9.00% | ||
Interest, frequency of payment | quarterly | ||
Term loan credit facility, expiation date | Feb. 7, 2023 | ||
Debt issuance costs, net | $ 731 | ||
Term loan credit facility, maturity term | 5 years | ||
2018 Credit Facility | Prior to February 7, 2021 | |||
Line Of Credit Facility [Line Items] | |||
Pre-payment fee, percentage | 2.00% | ||
2018 Credit Facility | February 7, 2021 to February 7, 2022 | |||
Line Of Credit Facility [Line Items] | |||
Pre-payment fee, percentage | 1.00% | ||
Term Loan | |||
Line Of Credit Facility [Line Items] | |||
Debt issuance costs, net | $ 1,399 | ||
Debt instrument, un-amortized discount | $ 1,160 |
Other Long-term Liabilities - S
Other Long-term Liabilities - Schedule of Other Long-term Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Other Liabilities Disclosure [Abstract] | ||
Deferred rent liability | $ 773 | $ 746 |
Leasehold improvements financing and other (see a and b below) | 94 | 128 |
Unrecognized tax benefits | 103 | 244 |
Deferred tax liability | 124 | |
Term Loan Credit Facility repayment fee (Note 10) | 619 | |
Other long-term liabilities | $ 1,094 | $ 1,737 |
Other Long-term Liabilities - A
Other Long-term Liabilities - Additional Information (Details) $ in Thousands | 12 Months Ended | ||||
Dec. 31, 2018CHF (SFr) | Dec. 31, 2017USD ($) | Jan. 31, 2014USD ($) | Jul. 31, 2013CHF (SFr) | May 31, 2013USD ($) | |
Facility in Switzerland | |||||
Schedule Of Other Long Term Liabilities [Line Items] | |||||
Line of credit facility, maximum borrowing capacity | SFr | SFr 400,000 | ||||
Line of credit | SFr 220,000 | $ 232 | |||
Principal and interest payment, start date | Jan. 1, 2014 | ||||
Principal and interest payment, end date | Dec. 31, 2018 | ||||
Line of credit facility, Interest rate | 5.00% | ||||
Facility in the U.S. | |||||
Schedule Of Other Long Term Liabilities [Line Items] | |||||
Line of credit | $ | $ 226 | $ 226 | |||
Principal and interest payment, start date | Jun. 1, 2013 | ||||
Principal and interest payment, end date | May 1, 2023 | ||||
Line of credit facility, Interest rate | 7.00% |
Other Long-term Liabilities -_2
Other Long-term Liabilities - Schedule of Leasehold Improvement Financing Repayments (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Other Liabilities Disclosure [Abstract] | ||
2,019 | $ 31 | |
2,020 | 29 | |
2,021 | 26 | |
2,022 | 27 | |
2,023 | 12 | |
Long-term debt | 125 | |
Less: current portion of long-term loans | (31) | |
Long-term loans, net of current portion | $ 94 | $ 128 |
Commitments and Contingent Li_3
Commitments and Contingent Liabilities - Additional Information (Details) - USD ($) $ in Thousands | Sep. 10, 2018 | Dec. 31, 2018 | Mar. 31, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Loss Contingencies [Line Items] | ||||||
Operating lease expiration description | The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2024. | |||||
Lease and rental expense | $ 4,033 | $ 3,474 | $ 2,748 | |||
Pledged bank deposits | $ 1,143 | 1,143 | 1,038 | |||
Operating Lease Commitments | 1,299 | 1,299 | $ 1,202 | |||
Settlement agreement date | February 10, 2015 | |||||
License and Collaboration Agreement (the “Zai Agreement”) | ||||||
Loss Contingencies [Line Items] | ||||||
Non-refundable up-front license fee, amount | $ 15,000 | |||||
License fees received | $ 12,700 | |||||
License and Collaboration Agreement (the “Zai Agreement”) | License | Accounting Standards Update 2014-09 | ||||||
Loss Contingencies [Line Items] | ||||||
Liability, revenue recognized | 767 | |||||
Settlement Agreement | ||||||
Loss Contingencies [Line Items] | ||||||
Settlement expense | $ 5,500 | |||||
Net sales milestone | $ 250,000 | |||||
Motor Vehicles | ||||||
Loss Contingencies [Line Items] | ||||||
Operating lease expiration description | The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2021. | |||||
Maximum | ||||||
Loss Contingencies [Line Items] | ||||||
Operating lease agreements, expiration year | 2,024 | |||||
Maximum | License and Collaboration Agreement (the “Zai Agreement”) | ||||||
Loss Contingencies [Line Items] | ||||||
Regulatory and commercial milestone payments | $ 78,000 | |||||
Maximum | Motor Vehicles | ||||||
Loss Contingencies [Line Items] | ||||||
Operating lease agreements, expiration year | 2,021 | |||||
Minimum | License and Collaboration Agreement (the “Zai Agreement”) | License | ||||||
Loss Contingencies [Line Items] | ||||||
Percentage of tiered royalties rates on net sales | 10.00% |
Commitments and Contingent Li_4
Commitments and Contingent Liabilities - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details) $ in Thousands | Dec. 31, 2017USD ($) |
Commitments And Contingencies Disclosure [Abstract] | |
2,019 | $ 3,807 |
2,020 | 3,053 |
2,021 | 2,549 |
2,022 | 2,282 |
2,023 | 1,530 |
Thereafter | 323 |
Total minimum lease payments | $ 13,544 |
Commitments and Contingent Li_5
Commitments and Contingent Liabilities - Additional Information (Details 1) | Dec. 31, 2018 |
License and Collaboration Agreement (the “Zai Agreement”) | License | Accounting Standards Update 2014-09 | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2019-01-01 | |
Loss Contingencies [Line Items] | |
Revenue recognition period | 6 years |
Income Taxes - Schedule of Inco
Income Taxes - Schedule of Income (Loss) before Income Taxes, Domestic and Foreign (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Income Tax Disclosure [Abstract] | |||
United States (U.S.) | $ (114,890) | $ (77,654) | $ (80,972) |
Non-U.S. | 68,948 | 29,157 | (40,492) |
Income (loss) before income taxes | $ (45,942) | $ (48,497) | $ (121,464) |
Income Taxes - Schedule of Comp
Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Current: | |||
U.S. | $ 6,701 | $ 8,491 | $ 6,501 |
Non-U.S. | 10,568 | 5,028 | 3,863 |
Total current | 17,269 | 13,519 | 10,364 |
Deferred: | |||
U.S. | (3) | 1 | |
Non-U.S. | 348 | (351) | 16 |
Total deferred | 348 | (354) | 17 |
Total income taxes provision | $ 17,617 | $ 13,165 | $ 10,381 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Income Taxes [Line Items] | |||
Statutory tax rate | 21.00% | 35.00% | 35.00% |
Tax benefit or expense recognized due to valuation allowance | $ 0 | $ 0 | $ 0 |
Deferred tax assets and liabilities related to revaluation | 34,800 | ||
Uncertain tax positions, interest and penalties recognized | 2 | $ 95 | $ 31 |
Luxembourg | |||
Income Taxes [Line Items] | |||
Net operating losses carryforward | $ 3,200 |
Income Taxes - Reconciliation o
Income Taxes - Reconciliation of Provision for Income Taxes (Details) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Income Tax Disclosure [Abstract] | |||
U.S statutory income taxes rate | 21.00% | 35.00% | 35.00% |
Non-deductible expenses | (2.20%) | (6.80%) | (2.50%) |
Foreign taxes rate differential | 13.20% | 15.10% | (14.20%) |
Change in valuation allowance | (62.30%) | (11.90%) | (30.00%) |
State income taxes | (4.50%) | 18.70% | 2.30% |
Share based compensation | (4.50%) | (4.50%) | 1.20% |
Change in unrecognized taxes expense | 0.30% | (0.80%) | (0.70%) |
Other | 0.70% | (71.90%) | 0.40% |
Effective taxes rate | (38.30%) | (27.10%) | (8.50%) |
Income Taxes - Summery of Net I
Income Taxes - Summery of Net Impact of the Tax Cuts and Jobs Act (Details) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Income Taxes [Line Items] | |||
U.S statutory income taxes rate | 21.00% | 35.00% | 35.00% |
Non-deductible expenses | (2.20%) | (6.80%) | (2.50%) |
Foreign taxes rate differential | 13.20% | 15.10% | (14.20%) |
Change in valuation allowance | (62.30%) | (11.90%) | (30.00%) |
State income taxes | (4.50%) | 18.70% | 2.30% |
Share based compensation | (4.50%) | (4.50%) | 1.20% |
Change in unrecognized taxes expense | 0.30% | (0.80%) | (0.70%) |
Other | 0.70% | (71.90%) | 0.40% |
Effective taxes rate | (38.30%) | (27.10%) | (8.50%) |
ETR before TCJA | |||
Income Taxes [Line Items] | |||
U.S statutory income taxes rate | 35.00% | ||
Non-deductible expenses | (6.80%) | ||
Foreign taxes rate differential | 15.10% | ||
Change in valuation allowance | (83.40%) | ||
State income taxes | 12.80% | ||
Share based compensation | 2.00% | ||
Change in unrecognized taxes expense | (0.90%) | ||
Other | (0.90%) | ||
Effective taxes rate | (27.10%) | ||
US Tax Cuts & Jobs Act Impact | |||
Income Taxes [Line Items] | |||
U.S statutory income taxes rate | 0.00% | ||
Non-deductible expenses | 0.00% | ||
Foreign taxes rate differential | 0.00% | ||
Change in valuation allowance | 71.50% | ||
State income taxes | 5.90% | ||
Share based compensation | (6.50%) | ||
Change in unrecognized taxes expense | 0.10% | ||
Other | (71.00%) | ||
Effective taxes rate | 0.00% |
Income Taxes - Schedule of Sign
Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Deferred tax assets: | ||
Allowance for doubtful accounts | $ 6,797 | |
Revenue recognition | $ 99,316 | 60,099 |
Net operating loss carryforwards | 843 | 972 |
Share based compensation | 10,886 | 7,544 |
Deferred revenue | 1,643 | 1,340 |
Other temporary differences | 1,384 | 1,147 |
Total gross deferred taxes assets | 114,072 | 77,899 |
Less: valuation allowance | (112,360) | (75,804) |
Total deferred taxes assets | 1,712 | 2,095 |
Deferred tax liabilities: | ||
Fixed assets | 1,427 | 1,486 |
Total gross deferred taxes liabilities | 1,427 | 1,486 |
Net deferred taxes assets | $ 285 | $ 609 |
Income Taxes - Schedule of Reco
Income Taxes - Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Income Tax Disclosure [Abstract] | |||
Balance at beginning of the year | $ 2,827 | $ 2,400 | $ 1,565 |
Additions (reductions) for taxes positions related current year | (141) | 55 | 1,088 |
Additions (reductions) for taxes positions related to prior years | (2,583) | 372 | 58 |
Additions (reductions) related to lapse of applicable statute of limitations | (311) | ||
Balance at the end of the year | $ 103 | $ 2,827 | $ 2,400 |
Share Capital - Schedule of Sha
Share Capital - Schedule of Share Capital (Details) - shares | Dec. 31, 2018 | Dec. 31, 2017 |
Share Based Compensation Allocation And Classification In Financial Statements [Abstract] | ||
Common stock, shares issued | 93,254,185 | 89,478,032 |
Common stock, shares outstanding | 93,254,185 | 89,478,032 |
Share Capital - Schedule of S_2
Share Capital - Schedule of Share Capital (Parenthetical) (Details) - $ / shares | Dec. 31, 2018 | Dec. 31, 2017 |
Share Based Compensation Allocation And Classification In Financial Statements [Abstract] | ||
Common stock, par value |
Share Capital - Schedule of War
Share Capital - Schedule of Warrants to Purchase Ordinary Shares that were Issued to Purchase of Convertible Preferred Shares (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Class Of Warrant Or Right [Line Items] | ||
Warrants for ordinary shares | 508,104 | |
Exercise price per share | $ 3.59 | $ 3.59 |
January 22, 2018 | ||
Class Of Warrant Or Right [Line Items] | ||
Expiration date | Jan. 22, 2018 | |
Warrants for ordinary shares | 203,241 | |
Exercise price per share | $ 3.59 | |
July 21, 2018 | ||
Class Of Warrant Or Right [Line Items] | ||
Expiration date | Jul. 21, 2018 | |
Warrants for ordinary shares | 304,863 | |
Exercise price per share | $ 3.59 |
Share Capital - Additional Info
Share Capital - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | Dec. 31, 2018 | Jan. 31, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2018 | Dec. 30, 2018 |
Share Capital [Line Items] | |||||||
Number of warrants cashless exercised | 504,225 | 1,418,711 | |||||
Warrants exercise price | $ 3.59 | $ 3.59 | $ 3.59 | $ 3.59 | |||
Credit facility repayment date | Dec. 31, 2013 | ||||||
Class of Warrant or Right, Date from which Warrants or Rights Exercisable | Jan. 31, 2016 | ||||||
Unrecognized compensation cost | $ 43,315 | $ 43,315 | $ 43,315 | ||||
Unrecognized compensation cost expected recognition weighted average period | 2 years 7 months 6 days | ||||||
Weighted average grant date exercise price of options granted | $ 23.73 | 10.53 | $ 7.37 | ||||
Weighted average grant date fair values options forfeited and cancelled | $ 15.09 | $ 12.54 | $ 9.72 | ||||
Aggregate intrinsic values options exercised | $ 57,813 | $ 17,945 | $ 7,637 | ||||
Fair value of ordinary shares | $ 33.48 | $ 33.48 | $ 20.20 | $ 7.85 | $ 33.48 | ||
ESPP | |||||||
Share Capital [Line Items] | |||||||
Ordinary shares available for grant | 3,122,410 | 3,122,410 | 3,122,410 | ||||
Percentage of increase in shares outstanding | 1.00% | ||||||
Option | |||||||
Share Capital [Line Items] | |||||||
Stock awards granted, vesting period | 4 years | ||||||
Stock awards granted, expiration period | 10 years | ||||||
RSUs | |||||||
Share Capital [Line Items] | |||||||
Stock awards granted, vesting period | 3 years | ||||||
2015 Plan | |||||||
Share Capital [Line Items] | |||||||
Percentage increase in number of shares available for issuance | 4.00% | ||||||
Number of shares available for issuance | 27,035,515 | 27,035,515 | 27,035,515 | 23,307,208 | |||
Ordinary shares available for grant | 13,843,105 | 13,843,105 | 13,843,105 | ||||
2015 Plan | Option | |||||||
Share Capital [Line Items] | |||||||
Stock awards granted, vesting period | 4 years | ||||||
Stock awards granted, expiration period | 10 years | ||||||
2015 Plan | RSUs | |||||||
Share Capital [Line Items] | |||||||
Stock awards granted, vesting period | 3 years | ||||||
Series H Convertible Preferred Shares | |||||||
Share Capital [Line Items] | |||||||
Warrants exercise price | $ 18.77 | $ 18.77 | $ 18.77 | ||||
Warrants issued to purchase of preferred shares | 975,644 | ||||||
Warrant | |||||||
Share Capital [Line Items] | |||||||
The Number of ordinary shares that originally could be purchased by exercise of warrants in cash | 3,879 | 6,498 | |||||
Warrants exercised to ordinary shares | 315,155 | ||||||
Warrant | Warrants Not Settleable in Cash | |||||||
Share Capital [Line Items] | |||||||
Number of shares issued upon the exercise of warrants | 437,081 | 803,138 | |||||
Ordinary Shares | |||||||
Share Capital [Line Items] | |||||||
Number of shares issued upon the exercise of warrants | 87,372 | ||||||
Issuance of shares in connection with employee stock purchase plan(in shares) | 167,433 | 92,388 | |||||
Ordinary Shares | ESPP | |||||||
Share Capital [Line Items] | |||||||
Issuance of shares in connection with employee stock purchase plan(in shares) | 347,193 |
Share Capital - Schedule of Fai
Share Capital - Schedule of Fair Value Assumptions Used Only for Equity Based Awards Estimated Using Black-Scholes Option Pricing Model (Details) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Stock Option Plans | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Expected term (years) | 6 years 3 months | ||
Expected volatility, minimum | 52.00% | 57.00% | 58.00% |
Expected volatility, maximum | 55.00% | 59.00% | 62.00% |
Risk-free interest rate, minimum | 2.70% | 1.97% | 1.23% |
Risk-free interest rate, maximum | 2.99% | 2.23% | 1.88% |
Dividend yield | 0.00% | 0.00% | 0.00% |
Stock Option Plans | Minimum | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Expected term (years) | 5 years 6 months | 5 years 6 months | |
Stock Option Plans | Maximum | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Expected term (years) | 6 years 3 months | 6 years 3 months | |
ESPP | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Expected term (years) | 6 months | 6 months | 5 months 1 day |
Expected volatility | 70.00% | ||
Expected volatility, minimum | 45.00% | 76.00% | |
Expected volatility, maximum | 53.00% | 82.00% | |
Risk-free interest rate | 0.40% | ||
Risk-free interest rate, minimum | 1.61% | 0.62% | |
Risk-free interest rate, maximum | 2.14% | 1.13% | |
Dividend yield | 0.00% | 0.00% | 0.00% |
Share Capital - Schedule of Sto
Share Capital - Schedule of Stock Options to Purchase Ordinary Shares (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Number of options | |||
Number of options, Outstanding at beginning of year | 14,806,027 | ||
Number of options, Granted | 2,520,502 | ||
Number of options, Exercised | (2,693,236) | ||
Number of options, Forfeited and cancelled | (195,078) | ||
Number of options, Outstanding at ending of year | 14,438,215 | 14,806,027 | |
Number of options, Exercisable options | 6,090,628 | ||
Weighted average exercise price | |||
Weighted average exercise price, Outstanding at beginning of year | $ 10.64 | ||
Weighted average exercise price, Granted | 23.73 | $ 10.53 | $ 7.37 |
Weighted average exercise price, Exercised | 6.89 | ||
Weighted average exercise price, Forfeited and cancelled | 15.09 | ||
Weighted average exercise price, Outstanding at end of year | 13.56 | $ 10.64 | |
Weighted average exercise price, Exercisable options | $ 11.04 | ||
Aggregate intrinsic value | |||
Aggregate intrinsic value, Outstanding at end of year | $ 287,706 | ||
Aggregate intrinsic value, Exercisable options | $ 136,695 |
Share Capital - Schedule of RSU
Share Capital - Schedule of RSU's (Details) - RSUs $ / shares in Units, $ in Thousands | 12 Months Ended |
Dec. 31, 2018USD ($)$ / sharesshares | |
Number of RSUs | |
Number of RSUs, unvested at beginning of year | shares | 1,651,219 |
Number of RSUs, granted | shares | 535,220 |
Number of RSUs, vested | shares | (556,563) |
Number of RSUs, forfeited and cancelled | shares | (16,679) |
Number of RSUs, unvested at ending of year | shares | 1,613,197 |
Weighted average grant date fair value price | |
Weighted average grant date fair value price, unvested at beginning of year | $ / shares | $ 9.66 |
Weighted average grant date fair value price, granted | $ / shares | 23.32 |
Weighted average grant date fair value price, vested | $ / shares | 9.90 |
Weighted average grant date fair value price, forfeited and cancelled | $ / shares | 15.79 |
Number of RSUs, unvested at ending of year | $ / shares | $ 14.04 |
Aggregate intrinsic value | |
Weighted average grant date date fair value price, unvested at ending of year | $ | $ 54,010 |
Share Capital - Equity-Based Co
Share Capital - Equity-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Total share-based compensation expense | $ 39,846 | $ 27,116 | $ 21,441 |
Cost of Revenues | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Total share-based compensation expense | 1,261 | 467 | 623 |
Research, Development and Clinical Trials | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Total share-based compensation expense | 4,709 | 3,587 | 3,155 |
Sales and Marketing | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Total share-based compensation expense | 7,393 | 3,784 | 5,111 |
General and Administrative | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Total share-based compensation expense | $ 26,483 | $ 19,278 | $ 12,552 |
Share Capital - Schedule of S_3
Share Capital - Schedule of Stock Option Outstanding (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Number of options outstanding | 14,438,215 | 14,806,027 |
Options outstanding, weighted average remaining contractual term | 7 years 3 months 7 days | |
Number of options exercisable | 6,090,628 | |
Options exercisable, weighted average remaining contractual term | 5 years 7 months 9 days | |
Exercise price 0.23 - 1.00 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Number of options outstanding | 46,045 | |
Options outstanding, weighted average remaining contractual term | 1 year 3 months 10 days | |
Number of options exercisable | 46,045 | |
Options exercisable, weighted average remaining contractual term | 1 year 3 months 10 days | |
Exercise price 0.23 - 1.00 | Minimum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 0.23 | |
Exercise price 0.23 - 1.00 | Maximum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 1 | |
Exercise price 1.01 - 7.00 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Number of options outstanding | 1,741,728 | |
Options outstanding, weighted average remaining contractual term | 3 years 5 months 4 days | |
Number of options exercisable | 1,664,228 | |
Options exercisable, weighted average remaining contractual term | 3 years 2 months 23 days | |
Exercise price 1.01 - 7.00 | Minimum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 1.01 | |
Exercise price 1.01 - 7.00 | Maximum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 7 | |
Exercise price 7.01 - 11.00 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Number of options outstanding | 3,358,859 | |
Options outstanding, weighted average remaining contractual term | 7 years 1 month 28 days | |
Number of options exercisable | 1,477,492 | |
Options exercisable, weighted average remaining contractual term | 5 years 10 months 28 days | |
Exercise price 7.01 - 11.00 | Minimum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 7.01 | |
Exercise price 7.01 - 11.00 | Maximum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 11 | |
Exercise price 11.01 - 16.00 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Number of options outstanding | 4,725,204 | |
Options outstanding, weighted average remaining contractual term | 7 years 5 months 4 days | |
Number of options exercisable | 1,745,554 | |
Options exercisable, weighted average remaining contractual term | 6 years 9 months 3 days | |
Exercise price 11.01 - 16.00 | Minimum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 11.01 | |
Exercise price 11.01 - 16.00 | Maximum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 16 | |
Exercise price 16.01 - 20.00 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Number of options outstanding | 298,637 | |
Options outstanding, weighted average remaining contractual term | 8 years 6 months 25 days | |
Number of options exercisable | 71,502 | |
Options exercisable, weighted average remaining contractual term | 8 years 6 months 25 days | |
Exercise price 16.01 - 20.00 | Minimum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 16.01 | |
Exercise price 16.01 - 20.00 | Maximum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 20 | |
Exercise price 20.01 - 27.50 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Number of options outstanding | 3,661,651 | |
Options outstanding, weighted average remaining contractual term | 8 years 6 months 25 days | |
Number of options exercisable | 1,073,462 | |
Options exercisable, weighted average remaining contractual term | 6 years 11 months 23 days | |
Exercise price 20.01 - 27.50 | Minimum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 20.01 | |
Exercise price 20.01 - 27.50 | Maximum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 27.50 | |
Exercise price 27.51 - 35.00 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Number of options outstanding | 606,091 | |
Options outstanding, weighted average remaining contractual term | 9 years 6 months 10 days | |
Number of options exercisable | 12,345 | |
Options exercisable, weighted average remaining contractual term | 9 years 5 months 1 day | |
Exercise price 27.51 - 35.00 | Minimum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 27.51 | |
Exercise price 27.51 - 35.00 | Maximum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price | $ 35 |
Financial Expenses, Net - Sched
Financial Expenses, Net - Schedule of Financial Expenses, Net (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Financial expenses: | |||
Interest expense | $ (13,491) | $ (10,261) | $ (5,937) |
Amortization of credit facility costs | (2,777) | (1,111) | (667) |
Foreign currency transaction losses | (398) | (396) | |
Others | (242) | (321) | (318) |
Financial expenses | (16,908) | (11,693) | (7,318) |
Financial income: | |||
Amortization of treasury bills premium | 1,986 | 859 | 512 |
Foreign currency transaction gains | 549 | ||
Interest income | 2,652 | 1,116 | 659 |
Financial income | 4,638 | 2,524 | 1,171 |
Total financial expenses, net | $ (12,270) | $ (9,169) | $ (6,147) |
Basic and Diluted Net Loss Pe_3
Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Ordinary Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||||
Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Earnings Per Share [Abstract] | |||||||||||||||
Net income (loss) attributable to ordinary shares as reported | $ (15,631) | $ (11,694) | $ (15,510) | $ (20,724) | $ (10,945) | $ (11,498) | $ (21,174) | $ (18,045) | $ (22,168) | $ (33,628) | $ (40,612) | $ (35,437) | $ (63,559) | $ (61,662) | $ (131,845) |
Shares used in computing net income (loss) per ordinary share, basic and diluted | 93,083,298 | 92,911,375 | 91,331,862 | 89,985,612 | 89,389,364 | 89,125,646 | 88,218,868 | 87,452,983 | 86,760,316 | 85,774,874 | 85,274,683 | 84,397,164 | 91,828,043 | 88,546,719 | 85,558,448 |
Net income (loss) per ordinary share, basic and diluted | $ (0.17) | $ (0.13) | $ (0.17) | $ (0.23) | $ (0.12) | $ (0.13) | $ (0.24) | $ (0.21) | $ (0.26) | $ (0.39) | $ (0.48) | $ (0.42) | $ (0.69) | $ (0.70) | $ (1.54) |
Supplemental Information - Sche
Supplemental Information - Schedule of Long-Lived Assets by Location (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Revenues From External Customers And Long Lived Assets [Line Items] | |||
Long-lived assets | $ 15,366 | $ 18,067 | $ 18,620 |
United States | |||
Revenues From External Customers And Long Lived Assets [Line Items] | |||
Long-lived assets | 8,289 | 10,372 | 11,981 |
Switzerland | |||
Revenues From External Customers And Long Lived Assets [Line Items] | |||
Long-lived assets | 2,513 | 5,114 | 4,346 |
Israel | |||
Revenues From External Customers And Long Lived Assets [Line Items] | |||
Long-lived assets | 2,236 | 2,081 | 1,915 |
Germany | |||
Revenues From External Customers And Long Lived Assets [Line Items] | |||
Long-lived assets | 1,054 | 190 | 49 |
Others | |||
Revenues From External Customers And Long Lived Assets [Line Items] | |||
Long-lived assets | $ 1,274 | $ 310 | $ 329 |
Supplemental Information - Sc_2
Supplemental Information - Schedule of Revenues by Geographic Region (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||||
Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Revenues From External Customers And Long Lived Assets [Line Items] | |||||||||||||||
Net revenues | $ 69,674 | $ 64,756 | $ 61,514 | $ 52,125 | $ 53,661 | $ 50,109 | $ 38,376 | $ 34,880 | $ 30,242 | $ 21,674 | $ 17,919 | $ 13,053 | $ 248,069 | $ 177,026 | $ 82,888 |
United States | |||||||||||||||
Revenues From External Customers And Long Lived Assets [Line Items] | |||||||||||||||
Net revenues | 168,414 | 134,688 | 72,771 | ||||||||||||
EMEA | |||||||||||||||
Revenues From External Customers And Long Lived Assets [Line Items] | |||||||||||||||
Net revenues | 73,304 | 42,035 | 10,028 | ||||||||||||
Japan | |||||||||||||||
Revenues From External Customers And Long Lived Assets [Line Items] | |||||||||||||||
Net revenues | $ 6,351 | $ 303 | $ 89 |
Supplemental Information - Sc_3
Supplemental Information - Schedule of Revenues by Geographic Region (Parenthetical) (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||||
Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Revenues From External Customers And Long Lived Assets [Line Items] | |||||||||||||||
Net revenues | $ 69,674 | $ 64,756 | $ 61,514 | $ 52,125 | $ 53,661 | $ 50,109 | $ 38,376 | $ 34,880 | $ 30,242 | $ 21,674 | $ 17,919 | $ 13,053 | $ 248,069 | $ 177,026 | $ 82,888 |
Germany | |||||||||||||||
Revenues From External Customers And Long Lived Assets [Line Items] | |||||||||||||||
Net revenues | $ 67,849 | $ 40,215 | $ 9,799 |
Selected Quarterly Financial _3
Selected Quarterly Financial Information (Unaudited) - Summary of Selected Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||||
Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Selected Quarterly Financial Information [Abstract] | |||||||||||||||
Net revenues | $ 69,674 | $ 64,756 | $ 61,514 | $ 52,125 | $ 53,661 | $ 50,109 | $ 38,376 | $ 34,880 | $ 30,242 | $ 21,674 | $ 17,919 | $ 13,053 | $ 248,069 | $ 177,026 | $ 82,888 |
Gross profit | 46,646 | 45,807 | 41,681 | 33,887 | 38,021 | 34,956 | 25,224 | 23,216 | 19,268 | 10,556 | 1,710 | 5,071 | 168,021 | 121,417 | 36,606 |
Operating income (loss) | (8,664) | (5,246) | (7,085) | (12,677) | (4,506) | (5,919) | (15,530) | (13,373) | (17,877) | (28,265) | (37,237) | (31,938) | (33,672) | (39,328) | (115,317) |
Net income (loss) | $ (15,631) | $ (11,694) | $ (15,510) | $ (20,724) | $ (10,945) | $ (11,498) | $ (21,174) | $ (18,045) | $ (22,168) | $ (33,628) | $ (40,612) | $ (35,437) | $ (63,559) | $ (61,662) | $ (131,845) |
Basic and diluted net income (loss) per ordinary share | $ (0.17) | $ (0.13) | $ (0.17) | $ (0.23) | $ (0.12) | $ (0.13) | $ (0.24) | $ (0.21) | $ (0.26) | $ (0.39) | $ (0.48) | $ (0.42) | $ (0.69) | $ (0.70) | $ (1.54) |
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share | 93,083,298 | 92,911,375 | 91,331,862 | 89,985,612 | 89,389,364 | 89,125,646 | 88,218,868 | 87,452,983 | 86,760,316 | 85,774,874 | 85,274,683 | 84,397,164 | 91,828,043 | 88,546,719 | 85,558,448 |
Subsequent Event - Additional I
Subsequent Event - Additional Information (Details) | Feb. 03, 2019 |
Subsequent Event | |
Subsequent Event [Line Items] | |
Plaintiff damages sought | Plaintiff is asking the court to issue an order (i) providing that he is the holder of 210,000 ordinary shares of the Company, or alternatively (ii) providing that he is entitled to receive from the Company and Prof. Palti 210,000 shares of the Company, and (iii) ordering that the Company’s register of shareholders be amended to reflect his ownership of such shares. |